






THE MICHAEL J.
FOX

FOUNDATION FOR
PARKINSON'S
RESEARCH



PROGRESS

ANNUAL REPORT 2009

THE MICHAEL J. FOX FOUNDATION IS DEDICATED TO FINDING A CURE FOR PARKINSON'S DISEASE THROUGH AN AGGRESSIVELY FUNDED RESEARCH AGENDA AND TO ENSURING THE DEVELOPMENT OF IMPROVED THERAPIES FOR THOSE LIVING WITH PARKINSON'S TODAY.



2	Letter From the CEO, Founder and Co-Founder
4	Scientific Progress Report
	High-priority Research Areas:
	The Science We're Most Excited About
	Transforming Basic Discoveries Into Therapeutic Targets
	Speeding Clinical Testing of New Interventions
	Mobilizing New Technologies and Tools in
	PD Therapeutic Development
18	Select List of Organizations with
	Active MJFF Awards in 2009
19	Select List of 2009 MJFF Workshops
	and Summit Meetings
20	2009 in Photos
22	2009 Donor Listing
40	Financial Highlights

Letter from the CEO, Founder and Co-Founder

In 2009, with the support of more than 56,000 individuals, corporations and foundations, The Michael J. Fox Foundation continued to invest where we saw potential to drive progress forward, pushing ourselves and our partners to ever-greater heights in pursuit of transformative treatments and a cure for Parkinson's disease.

Against an uncertain economic backdrop, we funded over \$39 million in targeted Parkinson's research — the most we've ever funded in one year — bringing our total research investments at year-end to nearly \$170 million. Yet those who know us know our core belief is that ending Parkinson's is not merely about spending more money, but about spending that money with impact. Last year we expanded our emphasis on critical research tools and patients' unmet needs while continuing to drive key next steps on top therapeutic targets. (Turn the page to read more about our high-priority research areas, the science we believe is closest or most critical to practical impact on patients' lives.)

Sitting at the hub of global PD research, our job is to act urgently and strategically to dismantle roadblocks and streamline the path to a cure. We talk — and listen — to the world's most prominent Parkinson's scientists from academic and industry labs about what they need and where new opportunities lie. Our staff, which includes both scientific PhDs and business-trained project managers, continually surveys a wide and complex field in order to prioritize the projects most needed to accelerate new therapies. We work to see the big picture, then invest our capital with one return in mind: speeding scientific solutions to the nearly five million people living with Parkinson's worldwide.

As Canada's *Globe and Mail* reported in September, our aggressive, entrepreneurial approach to science lies at the heart of our mission to find a cure for Parkinson's — and, in the process, to reshape the way medical research gets done. 2009 highlights include:

- Investing over \$11 million in biomarker development (bringing total funding in this area to over \$25 million) and laying the groundwork to sponsor the Parkinson's Progression Markers Initiative (PPMI), a landmark biomarker study launching in 2010. (While PPMI isn't covered in this report, you can learn more about it at michaeljfox.org/PPMI.)
- Allocating over \$3 million to pre-clinical models, including a grant to speed a cutting-edge gene knockout technology into Parkinson's therapeutic development within months of its advent. The technology was later named one of the top 10 scientific innovations of the year by *The Scientist*.
- Initiating a \$1-million clinical trial to establish a framework for the development of effective treatments for dyskinesia, the debilitating side effect of long-term dopamine replacement therapy.
- With lead support from The Edmond J. Safra Foundation, awarding \$2 million to drive development of treatment approaches for postural instability and gait disorder



(PIGD), a troubling constellation of symptoms that are poorly understood and respond inconsistently or not at all to dopamine replacement therapies.

■ With lead support from the Brin Wojcicki Foundation, executing an integrated, multi-million-dollar strategy to advance biological understanding of LRRK2, the single greatest known genetic contributor to Parkinson's disease, while simultaneously laying the groundwork for effective LRRK2 clinical trials in the future.

■ Launching PD Online Research (pdonlineresearch.org), a Web-based platform for research professionals to engage daily on key research hurdles and new findings. So far, nearly 2,000 Parkinson's researchers at all levels and from all over the world have become members.

We invite you to read more about these investments, and the potential we see in them to change the face of Parkinson's drug development, throughout this report and at michaeljfox.org.

Of course, effecting meaningful change in how new treatments are developed requires thoughtful strategies for engaging not only scientists but also patients and caregivers, policymakers and other research funders. That's why in 2009 we also focused on building and deepening our relationships and collaborations in every sector of the PD community. We chartered a Patient Council to provide input on our programmatic activities

from the critical perspective of those living with the disease. Our new Leadership Council is made up of generous advisors who provide leadership financial support and strategic insight about how we can more effectively engage new audiences to advance progress. And Team Fox, our grassroots fundraising network, continued to inspire and unite communities across the country in passionate pursuit of a cure.

Your dedication allows us to keep taking the risks that patients and their loved ones want taken in service of accelerating therapeutic breakthroughs. Our gratitude to you is as clear and strong as our vision of a world without PD.

Katie Hood
CEO

Michael J. Fox
Founder

Deborah W. Brooks
Co-Founder

High-priority Research Areas: The Science We're Most Excited About

While MJFF's portfolio of investments includes up to 250 active grants spanning Parkinson's therapeutic development, to achieve our mission of speeding the cure, we must strategically evaluate research hits and prioritize limited resources. This section provides an overview of our top priorities for funding and intellectual leadership. All are currently believed by our in-house research team and expert advisors to be critical areas of focus in our pursuit of transformative treatments for Parkinson's in the shortest possible timeframe. You'll find detailed stories about our work in these areas throughout this report.


Top Therapeutic Targets: Alpha-synuclein, LRRK2, Trophic Factors

Genetic targets Alpha-Synuclein and LRRK2. Though only a small fraction of people with Parkinson's carry mutations in PD-implicated genes, findings from genetic studies open new avenues toward treatments that will benefit everyone with the disease. Two genetic targets, alpha-synuclein and LRRK2, have risen to prominence for their exceptional promise to provide new treatment approaches to Parkinson's.

■ The gene known as alpha-synuclein produces a protein that aggregates to form Lewy bodies, microscopic clumps that are the pathological hallmark of PD. Though alpha-synuclein's precise role in PD remains unclear, growing evidence supports the idea that decreasing its levels in the brain could be one way to slow or stop Parkinson's progression. MJFF has invested more than \$32 million in alpha-synuclein research to date.

■ First linked to PD in 2004, mutations in the LRRK2 gene are now believed to be the most common genetic contribution to the disease. MJFF is driving a comprehensive strategy for advancing LRRK2 research. The goal is to shed light on the gene's biological role in PD while laying the groundwork for conclusive clinical trials. With lead support from The Brin Wojcicki Foundation, MJFF has invested over \$16 million in LRRK2 research to date.


Trophic factors. Trophic factors (also known as neurotrophic factors or growth factors) are specialized proteins that protect and nurture neurons, including the dopamine neurons that die in Parkinson's disease. While clinical trials involving trophic factors have not yielded hoped-for results, The Michael J. Fox Foundation continues to see great promise in trophic-based approaches to treating PD. The Foundation has invested over \$20 million in trophic factor research to date, and in 2009 earmarked another \$5 million under a 2010 *LEAPS* program to advance state-of-the-art trophic factor therapies into the clinic.



Cerebellum of a pre-clinical model created to overexpress the protein alpha-synuclein (shown in green), helping scientists understand possible toxic effects of increased levels of the protein in the brain.



SCIENTIFIC
PROGRESS
REPORT



Life and death of a neuron: Fluorescently labeled neurons show degenerative changes after expressing the mutant LRRK2 protein, the dominant genetic mutation that causes Parkinson's in humans. Neurons are labeled red; their nuclei are blue; LRRK2 is green. At left is a cell expressing the normal version of LRRK2; the cell has a normal appearance. At right is a cell expressing the mutated form of LRRK2; it is shrunken and the nucleus is starting to die.

Patients' Unmet Needs

Available treatments for Parkinson's leave several troubling symptoms of the disease entirely unaddressed. These include cognitive deficits and mood disorders, problems with posture and gait, and gastrointestinal (GI) problems such as constipation. Complications of current treatments, including dyskinesia (the excessive, uncontrollable movements that result from long-term dopamine replacement therapy), also diminish quality of life.

The Michael J. Fox Foundation is committed to providing the financial and intellectual leadership required to drive treatments for patients' unmet needs. Since its founding, MJFF has invested over \$11 million in dyskinesia research, including a major clinical trial launched in December 2009 to validate vitally needed clinical scales (see page 15). We have also funded millions of dollars in research toward alleviating untreated symptoms of PD — including developing the first pre-clinical models to mimic GI symptoms in Parkinson's and, with lead support from The Edmond J. Safra Foundation, our 2009 \$2-million initiative to drive treatments for postural instability and gait disturbances.

Critical Research Tools, New Technologies and Data Sharing

Pre-clinical models. With about \$13 million in investments, MJFF is a field leader in the development of improved models of PD that accurately mimic the human condition, allowing researchers to test potential disease-modifying therapies. And to ensure that new and better models get into scientists' hands as quickly and efficiently as possible, we also are developing practical, low-cost channels for worldwide distribution of these critical tools.

Biomarkers and clinical scales. To date we've invested nearly \$29 million in biomarkers and clinical scales, tools necessary for researchers to definitively assess treatment effects in clinical studies. In 2009 we launched an initiative to validate clinical scales used to measure changes in dyskinesia severity. We also laid the groundwork to sponsor a game-changing longitudinal study, PPMI, launching in 2010, that will identify and verify PD biomarkers — molecular or physiological characteristics that can be objectively measured and evaluated to provide clearer outcomes from clinical trials and lower the hurdle to industry investment in PD.

Leveraging new technologies in PD. Research technologies emerge and evolve at a rapid pace. We monitor these developments and apply funding to strategically leverage those that could impact Parkinson's science. In 2009 one such technology was named to *The Scientist's* list of the top 10 scientific innovations of the year (see page 16).

Data sharing. New technologies and systems could revolutionize the way researchers communicate and share information. In addition to our ongoing activities to facilitate data exchange between and among academic and industry researchers, in 2009 we launched PD Online Research (PDOR) (www.pdonlineresearch.org). PDOR enables collaboration, instant communication and rapid problem-solving among scientists around the globe. Its goal is straightforward: enable quicker knowledge turns and faster progress toward therapeutic breakthroughs. By the end of the year, PD Online Research had almost 2,000 members from government, industry and academic sectors.

Transforming Basic Discoveries Into Therapeutic Targets




Basic discoveries about the biological mechanisms of Parkinson's disease are critical to the development of new therapies. Equally important, however, is a focused and deliberate effort to shepherd these discoveries through the complex process of therapeutic development and determine their real potential as breakthrough treatments. The stories on these pages illustrate MJFF's unique role in partnering with researchers to put the most promising results on a fast track toward practical relevance in patients' lives.

Going Viral: Could a Virus's RNA Help Protect Neurons?

Molecular virologist John Sinclair, PhD, of the University of Cambridge wasn't even thinking about Parkinson's when he discovered a previously unknown piece of viral RNA that keeps cells alive during infection. But his work on infectious disease elucidated an intriguing possibility: Could viral RNA protect the neurons that die in PD, thus modifying disease progression, something no current treatment has been proven to do?

MJFF quickly came on board to help him find out. With fast funding under MJFF's *Rapid Response Innovation Awards*, Dr. Sinclair successfully engineered a form of the viral RNA suitable for pre-clinical testing, and his team demonstrated its ability to protect neurons in parkinsonian models. The Foundation then provided follow-on funding for Dr. Sinclair's team to investigate the potential of the RNA complex to restore function to already-damaged neurons.

"PD patients have lost a substantial percentage of their dopaminergic neurons by the time of diagnosis," says Dr. Sinclair. "So the real question is whether this complex can stop that process, preventing the disease from progressing further." His group is also working to identify the specific region of the viral RNA responsible for the protective effects. "The more we can refine the RNA complex," he explains, "the quicker we'll be able to deliver a therapy from bench to bedside."



In the upper panels, the blue dopamine neurons at left are exposed to a toxin and die, as shown by the red marker for cell death at right. In the lower panels, the dopamine neurons at left have been treated with therapeutic RNA. As a result the cells do not die when exposed to the toxin, and no red cell death marker is visible at right.

“You don’t gain much by keeping things under wraps. Actually getting different people with different viewpoints and different techniques to work together in an open fashion rapidly speeds up progress.”

*Patrick Lewis, University College London,
MJFF LRRK2 Biology Consortium member*

Sharing the Wealth (of Data): A Consortium Approach to Speed LRRK2-based Treatments

The LRRK2 gene holds tremendous promise as a therapeutic target for PD. Not only is it the single most common contributor to genetic cases of the disease, but it is a kinase — a type of cellular enzyme that is often highly druggable. Since LRRK2 was first linked to Parkinson’s disease in 2004, it has reinvigorated the field of Parkinson’s genetics and become the focus of intensive investigation by research teams all over the world.

MJFF’s research staff, in concert with the world’s leading experts in Parkinson’s genetics, has moved quickly to integrate global LRRK2 efforts into a united and streamlined scientific movement that will help minimize the timeline to practical LRRK2-based therapies. In 2009 MJFF homed in on collaborative efforts to increase understanding of LRRK2 biology, including convening a major LRRK2 summit at the end of the year. The spirit of collaboration was also extended to MJFF’s search for investigative teams to join a LRRK2 biology consortium aiming to fast-forward efforts to understand LRRK2 biology and target its vulnerabilities.

“This is a critical early moment in LRRK2 therapeutic development,” says Brian Fiske, PhD, associate director, team leader, Research Programs. “MJFF recognized the opportunity to transcend the disparate, one-off efforts that all too often characterize scientific discovery and instead lead a strategic new approach that hits on multiple fronts simultaneously.”

The journal *Nature Medicine* wrote: “To foster synergies moving forward, MJFF... established an international consortium to focus on one of the most promising candidate drug targets of the neurodegenerative disease. Under the terms of the two-year, \$3.5-million grant design, members of the consortium, which includes both academic and industry partners, will be compelled to share results and collaborate with one another on an ongoing basis to help accelerate therapeutic discoveries.”

Nine different research teams are members of the LRRK2 biology consortium. They are working to help elucidate the functions of LRRK2 in the cell, identify other cellular proteins linked to LRRK2 (called substrates) and develop critical tools to drive further research. Several groups are using complementary approaches to investigate related questions around LRRK2. For example, three teams investigating substrates are using different types of tissues for each project, which will allow for faster and more efficient cross-validation of any findings.

“Getting people working together on LRRK2 research increases the pool of ideas and expertise to draw from, and it builds in a way to check your work with others, which is unfortunately rare in science,” says Mark Cookson, PhD, a member of the MJFF Scientific Advisory Board and world-renowned expert on the cell biology of PD. “It will also help to keep people involved in the field, pushing forward to the next level that much faster. It’s an approach grounded in common sense.”

30 Number of labs funded by MJFF in 2009 that had never worked in PD before

\$6.6 million Amount of 2009 research funded by MJFF in those labs

Leverage: MJFF's Industry Strategy Bears Fruit

\$28.7 million

2009 MJFF
funding to
academic/
nonprofit teams

\$10.2 million

2009 MJFF
funding to
industry teams

With over 55 currently active industry collaborations and more than 85 since MJFF's inception, there is little doubt of the Foundation's commitment to partnering with biotech and pharmaceutical companies to speed treatments toward clinical testing and patients. But the greater goal of the Foundation's "de-risking" strategy is to create momentum and induce industry players to commit their own significant resources to pre-clinical and clinical Parkinson's therapeutic development programs.

"We look for leverage everywhere," says Debi Brooks, MJFF co-founder. "That means identifying the projects where it's a good bet that our investment of, say, a few hundred thousand dollars can create a tipping point and increase the odds of a company investing millions down the line."

Throughout 2009, mounting evidence suggested that MJFF has made several good bets on industry so far.


For example, Intra-Cellular Therapies, Inc. has been funded by the Foundation since 2006 to develop a small-molecule drug to increase the potency of levodopa, enabling relief of motor symptoms

at lower doses and reducing dyskinesias. With positive outcomes in several relevant models of PD, principal investigator Gretchen Snyder, PhD, received supplemental funding in 2009 for what will likely be the final pre-clinical work required before a Phase 1 clinical trial.

Amicus Therapeutics of New Jersey also received MJFF funding in 2006 to test an orally administered small molecule with promise to decrease alpha-synuclein clumping, a hallmark of PD pathology. When the MJFF-funded test of a chaperone in a pre-clinical model of PD resulted in intriguing efficacy and dosing data, Amicus launched an internal PD drug development program. The company now expects to complete advanced pre-clinical proof-of-concept studies in Parkinson's disease during the course of 2010 and to report additional data in the second half of the year.

"The support we received from The Michael J. Fox Foundation was a key factor in our decision to commit to a Parkinson's program," says John F. Crowley, chairman and CEO of Amicus. "In 2010 we expect to make significant progress in our pre-clinical programs in Parkinson's disease."

With funding from The Michael J. Fox Foundation, Intra-Cellular Therapies Inc (ITI) is developing therapeutics to promote the intracellular response of brain cells to dopamine and restore the functions of dopamine that are lost in Parkinson's disease. In the schematic at right, dopamine, released from nerve terminals, interacts with receptor proteins to produce intracellular changes in second messengers and protein kinases that control the activity of brain cells through effects on different classes of proteins, including neurotransmitter receptors, ion pumps, ion channels and transcription factors. Based on the work of Paul Greengard, Nobel Laureate in Physiology & Medicine (2000).





UPDATE

A Major Milestone for Glutamate and PD

MJFF's 2008 annual report highlighted the work of *LEAPS* awardee P. Jeffrey Conn, PhD, who is pursuing an entirely new kind of symptomatic treatment for PD that would target glutamate — a molecule that, like dopamine, helps the brain send messages to the body. In 2009 Dr. Conn's team at Vanderbilt University hit a major scientific milestone. "We discovered systemically active molecules and verified that they were beneficial in a pre-clinical model of PD," says Dr. Conn. His team is now examining the effects of chronic dosing with these agents, testing their effects on subtle aspects of motor function in less severely parkinsonian models, and optimizing their drug-like characteristics. While there are no guarantees, if all goes well, the researchers could launch a clinical study in Parkinson's patients by 2013.


Jeff Conn and Colleen Niswender

G-CSF: A New Trophic Factor Approaches the Clinic

In 2006 researchers Mathias Baehr, MD, and Jochen Weishaupt, MD, of University Hospital Goettingen in Germany approached MJFF to discuss a growth factor called G-CSF (granulocyte-colony stimulating factor). G-CSF, already approved by the U.S. Food and Drug Administration to treat complications of chemotherapy in cancer patients, was believed to reduce cell death in a pre-clinical model of Parkinson's disease. The researchers were awarded funding under MJFF's *Target Validation* program to gather additional data critical for advancing to clinical trials in PD patients, such as an effective dose range.

In results published in the *Journal of Neurochemistry* and *BMC Neuroscience*, and presented at the Foundation's third annual PD Therapeutics Conference in September 2009, the researchers conclusively demonstrated that G-CSF was protecting neurons in a PD model; they also shed light on how it was achieving this beneficial effect. The researchers then ran extensive pre-clinical studies on an enhanced form of G-CSF called pegfilgrastim, which minimizes side effects and remains in the system longer.

Within months, MJFF granted follow-on funding for final pre-clinical studies in another relevant Parkinson's model. "We will monitor the effects of pegfilgrastim over time, look for any side effects and precisely measure its ability to reduce cell loss and improve motor symptoms in pre-clinical models," says Dr. Weishaupt. "If all goes well, this will be the final step before a clinical study to test safety in Parkinson's patients."



Protein structure of G-CSF


Speeding Clinical Testing of New Interventions



MJFF shares patients' urgency to bring new and better Parkinson's therapies to market as fast as possible. In prioritizing clinical trials, we emphasize proof-of-principle and first-in-human studies that can alter the risk profile of a given treatment. We also help assemble and organize teams, lend expertise to biotech and pharmaceutical companies testing or going deeper into PD waters, vet the Parkinson's potential of drugs approved for other diseases, and sponsor trials where intellectual property or patent issues reduce companies' incentive to get involved.



Marina Emborg



Chemical structure of pioglitazone

How Sweet It Is: A Diabetes Drug that Could Modify Progression of PD

When reports of the anti-inflammatory properties of the diabetes drug pioglitazone began to surface in the early 2000s, scientists saw an opportunity to translate these findings into therapies for multiple diseases where inflammation is a contributing factor, including Parkinson's disease. In 2002, this promising avenue of research was given a boost when pioglitazone was shown to prevent the death of dopamine neurons in pre-clinical models of PD.

In 2005, Marina Emborg, MD, PhD, director of the Preclinical Parkinson's Research Program at the University of Wisconsin, received an MJFF *Community Fast Track* award to test the neuroprotective properties of orally administered pioglitazone in more relevant pre-clinical models of PD.

"We knew that pioglitazone might one day provide an innovative, simple and non-invasive strategy to prevent Parkinson's progression," says Dr. Emborg. "Furthermore, since pioglitazone is already known to be safe, it could be quickly translated into clinical trials in PD patients. MJFF funding was vital to our efforts to provide proof-of-principle for a new class of compounds to treat PD and other neurodegenerative disorders."

When Dr. Emborg's preliminary data suggested that the active compounds of pioglitazone were neuroprotective, MJFF provided supplemental funding to determine whether the doses used in pre-clinical models could be translated to humans. This work will provide critical data on optimal dosage to inform a clinical trial in PD patients slated to launch in 2010 with significant funding from NINDS, the National Institute of Neurodegenerative Disease and Stroke (NIH).

"Repurposing existing drugs for Parkinson's could be a key approach to creating new and better treatment options for patients," says Todd Sherer, "but it's difficult for scientists to get funding for this kind of work. MJFF is committed to driving such efforts for the benefit of people living with the disease, and uniquely poised to do so."

"I know a lot of foundations, and [MJFF is] amazingly well-organized, and they care. They really care what happens. I've never experienced this before. It's a unique situation. That is why they are so successful."

Wolfgang Oertel

\$29.4 million

2009 MJFF funding
to U.S.-based
research teams

\$9.5 million

2009 MJFF funding
to international
research teams



Wolfgang Oertel



Lighting Up the Connection between Tobacco and Parkinson's Disease

Researchers and patients have long been intrigued by the link between tobacco and Parkinson's disease. "There have been numerous compelling observations to suggest that tobacco exposure may hold multiple benefits for PD patients," says Carlie Tanner, MD, one of the world's leading experts on environmental factors in PD and a member of the MJFF Scientific Advisory Board. "Epidemiological studies consistently demonstrate that tobacco use lowers the risk of developing Parkinson's disease, and experiments in pre-clinical models have shown that nicotine may protect dopaminergic cells from death. Several studies also suggest a symptomatic effect, though small and somewhat variable. And recent data shows that nicotine may reduce levodopa-induced dyskinesias."

Yet key questions about the relationship among smoking, nicotine and Parkinson's — including whether the protection seemingly conferred by smoking tobacco products stems from the nicotine in those products, other components of tobacco, or metabolic aspects related to smoking itself — remain unanswered.

In 2009 The Michael J. Fox Foundation awarded \$1.1 million for NIC-PD, an international clinical trial vetting the effects of nicotine skin patches on Parkinson's disease. It is the first long-term clinical trial expressly designed to test whether nicotine may in fact modify the progression of PD.

The double-blind, placebo-controlled trial — the first-ever multisite, investigator-initiated collaboration between Parkinson's research groups in Germany and the United States — will be conducted over three years in 150 newly diagnosed

Parkinson's patients. (Study participants will be treated and observed for one year.) Principal investigators Wolfgang H. Oertel, MD, and Marcus M. Unger, MD, of Philipps University Marburg, Germany, and Karl Kiebertz, MPH, of the University of Rochester, New York, will evaluate the disease-modifying potential of transdermal nicotine using standard nicotine skin patches of the type used by millions of smokers as a quitting aid.

Speaking to the journal *CenterWatch Monthly*, which reported on NIC-PD in its story "Michael J. Fox Foundation Gives German Investigator-initiated Trial New Life," Dr. Oertel said: "I know a lot of foundations, and [MJFF is] amazingly well-organized, and they care. They really care what happens. They go to the advisory board meetings. [Usually,] the advisors meet without the scientists and then they are called in and either their head is chopped off or they get the check. But, at Michael J. Fox, you meet for two days with the advisors and they go with you through all the topics. It's amazing. I've never experienced this before. It's a unique situation. That is why they are so successful."

"There's no doubt that the epidemiological data on smoking and PD is intriguing," says Katie Hood, CEO. "Our priority is on taking action to validate this data clinically in order to potentially translate it into a practical, patient-relevant therapy."

Targeting Glutamate to Treat Levodopa-induced Dyskinesias



Angela Cenci-Nilsson

Warning

An important cautionary note: While MJFF is funding clinical trials on supplements and drugs already available for purchase or prescription, people with Parkinson's (other than those who ultimately enroll in these trials) should not begin taking these agents as part of a Parkinson's disease treatment regimen without the explicit recommendation of their doctor. Evidence to date has not yet definitively proved a benefit in PD, and these substances carry potential health risks, which doctors will carefully monitor in trial participants. It is crucial that all care and treatment decisions related to Parkinson's disease and any other medical condition be made in consultation with a physician or other qualified medical professional.


Developing effective treatments to alleviate dyskinesias — the disruptive, involuntary movements that are a side effect of long-term dopamine replacement therapy — is a high-priority research area for MJFF. In 2009 one promising approach involving glutamate — a neurotransmitter of increasing interest to PD researchers — moved forward to the early stages of clinical research. MJFF has been a champion of an approach targeting a specific glutamate receptor, mGluR5, since 2005. The Foundation's de-risking efforts have now chaperoned mGluR5 from basic discovery to clinical testing and attracted industry interest in the target.

“Finding new and safe treatments that can prevent dyskinesias would allow patients to continue on levodopa, benefiting from its full symptomatic efficacy even in advanced stages of the disease,” says Todd Sherer, PhD, vice president, Research

Programs. “This would lead to an enormous improvement in patients’ quality of life.”

The initial data on mGluR5 and dyskinesia came from Angela Cenci-Nilsson, MD, PhD, of Lund University in Sweden. In 2005 Dr. Cenci-Nilsson received a *Target Validation* award to demonstrate that blocking the action of one particular receptor, mGluR5, prevented levodopa-induced dyskinesias in rodent models of PD.

The Foundation quickly provided follow-on funding for Dr. Cenci-Nilsson to partner with Erwan Bezard, PhD, of the University of Bordeaux in France. Their goal: take preliminary results to the next level in a more relevant model of PD. The pair worked closely with MJFF research staff to identify a compound capable of reducing mGluR5 activity. Finding one already in human clinical testing for another disease, they adapted their studies to this compound to accelerate development toward the clinic.



Abnormal involuntary movement scores, a measure of dyskinesia severity, increase over time in parkinsonian models treated with levodopa (represented by red squares). This increase is blunted in models receiving treatment with an mGluR5 antagonist as an add-on to levodopa (represented by blue triangles). The mGluR5 antagonist alone does not induce any abnormal involuntary movements (represented by yellow circles). Each data point represents the average value from eight to 10 models in each group.

“The Michael J. Fox Foundation’s staff are highly committed, truly capable people. They monitor your progress; they’re extremely aware of where Parkinson’s research is going and where it needs to go. They won’t fund a project just because it’s trendy, or because of a scientist’s famous name. Their goal is to promote quality research with high translational value, and they do everything to achieve that goal.”

Angela Cenci-Nilsson

MJFF is now partnering with Danna Jennings, MD, of The Institute for Neurodegenerative Disorders in New Haven, Connecticut, to verify the action of this compound and determine a safe and effective dose for use in future clinical trials. Using PET scans and a fluorescent imaging molecule that binds to mGluR5, Dr. Jennings images PD patients’ brains before and after treatment. “An important step before investing in a large clinical trial is to make sure that the drug is in fact getting to the brain and binding to the expected targets,” says Dr. Jennings. “Is the drug reaching the brain at appropriate levels?

What is the dose most likely to provide meaningful clinical benefit? Our research aims to answer these questions.”

MJFF’s commitment has galvanized the field, prompting industry scientists to conduct clinical testing of other compounds targeting mGluR5. “By driving pre-clinical development of promising drug targets, MJFF is providing tangible incentives for industry to increase its involvement in Parkinson’s research,” concludes Dr. Sherer. “The development of dyskinesia therapies based on mGluR5 activity is a perfect example of this strategy.”

\$10.1 million


Amount of research funded by MJFF in 2009 to address patients’ unmet needs including dyskinesia

UPDATE

Serotonin and Dyskinesia: MJFF Support Leads to Pilot Clinical Trial

Progress 2008 featured the efforts of Anders Björklund, PhD, and his colleague, Manolo Carta, PhD, of Lund University in Sweden to develop a new treatment for dyskinesia targeting the brain’s serotonin system, better known for its role in clinical depression. With Foundation funding, the researchers have now demonstrated that abnormal, dyskinesia-inducing dopamine release can be effectively blocked by drugs that act on two specific receptors, known as 5-HT1A and 5-HT1B, located on the serotonin neurons. They have also shown that this technique is particularly effective when the two receptors are activated simultaneously.

Based on these results, Dr. Björklund’s team is now conducting an MJFF-funded pilot clinical trial in 24 Parkinson’s patients at Lund University Hospital and Karolinska Hospital Huddinge (both in Sweden). The trial is being carried out in collaboration with the U.S. biotech company PsychoGenics, using their proprietary drug Eltoprazine, which activates both 5-HT1A and 5-HT1B and has shown promising results in pre-clinical trials to date.



Structure of the neurotransmitter serotonin

Mobilizing New Technologies and Tools in PD Therapeutic Development



To advance therapeutic targets toward the clinic requires highly specialized tools and technologies, whose development in itself requires significant financial and intellectual investment. But there is no financial incentive for any single stakeholder to allocate major funding to this critical need. MJFF, with its singular focus on patient-relevant outcomes, is uniquely positioned to marshal the resources and partners that can propel development of tools and technologies with potential to move the entire field forward.

Using Virtual Reality to Address Freezing of Gait

An MJFF-funded team in Sydney, Australia, is using functional magnetic resonance imaging (fMRI) in a virtual environment to visualize patients' brains while safely triggering freezing of gait episodes. The project is part of a \$2-million MJFF commitment to therapeutic development for postural instability and gait disturbances in Parkinson's disease, made possible with lead funding from The Edmond J. Safra Foundation.

While lying in the MRI scanner, patients will use foot pedals to 'walk' through a realistic three-dimensional environment they see on a small screen. The virtual environment task will probe cognitive processes that often provoke freezing episodes (such as sliding doors) or alleviate them (such as striped floors).

"We hypothesize that rather than simply reflecting a process related to gait, freezing episodes are in fact related to a breakdown in the circuitry that coordinates different functions such as movement and thinking," says principal investigator Simon Lewis, MD. "We want to identify the abnormal pattern of brain activation — hopefully increasing understanding of freezing and opening new directions for targeting therapy."



Simon Lewis

"Throughout all my experiences with MJFF I've been impressed with the rigor and accountability of the Foundation's process, and with the creative and competent way that the staff goes about its mission of finding better treatments and a cure for Parkinson's disease. I'm willing to dedicate as much time and effort to the Foundation as I do because I truly believe this organization is going to make a difference."

Gene Johnson, PhD, Chief Scientific Advisor, MJFF

Maximizing Learning from At-risk Populations: MJFF Drives LRRK2 Cohort Studies in New York, Tel Aviv and Tunisia

On page 7 you read about the LRRK2 biology consortium, part of MJFF's strategy to increase understanding of the LRRK2 gene that is believed to be the single most common contributor to genetic cases of Parkinson's disease. The Foundation is simultaneously working to define the clinical impact of LRRK2 on PD — that is, how LRRK2 may cause or prevent specific symptoms, impact rate of progression, or otherwise affect disease severity and trajectory.

The Foundation is funding two research teams to study PD in cohorts of Ashkenazi Jews and North African Arab-Berbers, two populations with a significantly elevated incidence of the PD-implicated LRRK2 mutation known as G2019S. What they learn will not only provide answers about what it means to have a LRRK2 mutation, but also open new avenues of therapeutic development for people with the far more common sporadic form of the disease.


A team of investigators from Mayo Clinic, Jacksonville, and the Institute of Neurology in Tunis is following an Arab-Berber cohort in Tunisia. A second group comprising investigators at Beth Israel Medical Center, Columbia University, Tel Aviv Sourasky

Medical Center and the Institute for Neurodegenerative Disorders is tracking Ashkenazi Jews in New York and in Tel Aviv, Israel.

"Not all people with LRRK2 mutations get PD, and for those who do develop the disease, there is great variability in symptoms," says Susan Bressman, MD, of Beth Israel Medical Center, coordinating principal investigator for the New York/Tel Aviv cohort. "By studying large numbers of people with the same mutation, we can start to understand its implications for risk and disease course in individuals."

To ensure that all data collected can be analyzed, shared and compared as efficiently and meaningfully as possible, MJFF worked with the investigators to set up collection methods standardized across both cohorts. This will improve the ability of the researchers to compare results and link clinical features to underlying biological and genetic processes.

"By studying these uniquely affected populations, our goal is to make drug development efforts centered on LRRK2 more efficient and ultimately speed patient-relevant outcomes from this work," says Katie Hood, CEO.



A Critical Step toward Controlling Dyskinesia

The drug levodopa is the gold-standard treatment for relieving the stiffness, tremors and rigidity of PD. But patients are forced to weigh symptomatic relief against the knowledge that, at some point, levodopa will very likely cause dyskinesia. Patients wait as long as possible to begin levodopa; even after starting, many limit dosage to reduce the risk of dyskinesia. If dyskinesia develops, patients often reduce their levodopa dose and settle for a lesser benefit from the best medical therapy available for their disease.

Dyskinesia is a moving target in every sense of the phrase. It takes different forms and varies widely from day to day and even hour to hour. Partly for this reason, the development of accurate clinical scales to detect type, severity, duration, and impact on the patient has been elusive. While several scales exist, their effectiveness has never been rigorously compared. Without scales the scientific community has confidence in, there is no framework for clinical testing of possible new treatments. This in turn creates a hurdle to biotech and pharmaceutical companies investing in the development of potential new dyskinesia therapies.


In 2009, as part of its ongoing efforts to drive new dyskinesia treatments, The Michael J. Fox Foundation announced a \$1-million clinical study to validate effective dyskinesia scales. The multi-site study, led by Christopher Goetz, MD, at Rush University Medical Center in Chicago, will aim to conclusively identify the scales that most accurately measure dyskinesia.

The experimental design involves amantadine, a current, albeit inadequate, drug frequently used off-label to treat dyskinesia. Patients will be treated with amantadine or placebo, and then have their dyskinesia rated over the course of several weeks using numerous dyskinesia measurement scales. (The researchers will examine the response to placebo as well, in order to favor scales that maximally separate placebo-associated changes from amantadine-associated changes.) The results will establish a path for clinical testing of future promising novel dyskinesia treatments, increasing the likelihood of industry investment in future clinical trials.

Model Techniques for Speeding PD Drug Development

Pre-clinical models are vital tools for drug development. Researchers require good models to increase understanding of cellular, molecular and behavioral aspects of disease, as well as to screen potential new therapies before they move forward to testing in humans. Parkinson's therapeutic development is held back by the lack of any pre-clinical model that accurately recapitulates both the underlying processes, and the symptoms, of the human condition. Even when good models are developed, better distribution channels are required to quickly get them into researchers' hands.

Zinc Finger Nuclease (ZFN) must be delivered as a pair to be functional. When all ZFN components are properly assembled, a highly specific pair of 'genomic scissors' is created.



The development and distribution of improved models is a major priority for MJFF, and in 2009 the Foundation's efforts bore significant fruit.

Knocking out PD

A laboratory technique known as gene knockout lets scientists working in pre-clinical models remove a specific gene of interest, effectively turning it off ("knocking it out"), allowing them to study genes' effects on cellular disease processes. Gene knockout has been used for decades in laboratory mice, but never successfully in rats until July 2009, when biotech Sigma-Aldrich published proof-of-principle for the first knockout rats.

"Rats offer numerous advantages as models for Parkinson's drug development," says Todd Sherer, PhD, vice president, Research Programs. "They

more closely mimic many behavioral aspects of human Parkinson's disease, offer a greater amount and wider range of tissue for testing and allow scientists to conduct certain tests that are impossible in mice or non-mammalian models."

Sigma-Aldrich used a novel technology called Zinc Finger Nuclease (ZFN). It causes targeted breaks in double-stranded DNA that can snip out specific genes of interest. ZFN was developed by Sangamo BioSciences and licensed to Sigma-Aldrich in 2007. Its application in rats would later be named one of the top 10 scientific innovations of 2009 by *The Scientist*.

By August MJFF had awarded a Sigma-Aldrich team led by Edward Weinstein, PhD, a one-year grant to develop five Parkinson's knockout models, each lacking one gene known to play a role in PD: alpha-synuclein, LRRK2, DJ-1, Parkin and PINK1. The creation of knockout rat models of PD will provide new opportunities for understanding the functions of different PD-implicated genes. The researchers expect to report back to MJFF on the creation and characterization of their models by mid-2010.

A pre-clinical model shows the effects of a human LRRK2 mutation

In 2009, with funding from MJFF under the *Development of Progressive Pre-clinical Models of PD* initiative, CJ Li, PhD, of Weill Cornell Medical College published the first reported mouse model for the study of LRRK2 gene mutations. (Read more about LRRK2 on page 4). Unlike the knockout rats, Dr. Li's mouse models express the human LRRK2 gene, allowing scientists for the first time to evaluate the progressive effects of these gene mutations — a critical step in the process of converting genetic discoveries into patient-relevant therapies and a vital need for biotech and pharmaceutical companies working to develop new treatments for Parkinson's.

"Dr. Li's models represent a much-needed pre-clinical tool to screen and validate potential new therapies for Parkinson's disease," says

“The Michael J. Fox Foundation for Parkinson’s Research didn’t waste any time putting recently published knockout rat technology to work.”

Science-Business eXchange (cover story), October 22, 2009

5

MJFF partner Sigma-Aldrich’s position in *The Scientist’s* Top 10 scientific innovations of 2009 for its novel knockout-gene technology

MJFF Scientific Advisory Board member Kalpana Merchant, PhD, of Eli Lilly and Co. “They also can be used to study the underlying mechanisms of LRRK2 mutations and how they contribute to PD.”

MJFF has quickly provided supplemental funding to Dr. Li and collaborator J. Timothy Greenamyre, MD, PhD, of the University of Pittsburgh to further characterize neurobehavioral deficits, neurochemical irregularities, dopamine cell loss, neuropathology, and molecular features in models of different ages.

“We anticipate that these models of PD will recapitulate various components of the human disease,” says Dr. Li. “This increases the potential that meaningful comparisons can be made between what we find in the models and what is seen in PD patients.”


Practical distribution channels for widespread access to the best tools

To reduce the costs and improve the speed and efficiency of producing and distributing research

models, in 2009 MJFF partnered with The Jackson Laboratory (JAX) in Bar Harbor, Maine, to strengthen JAX’s existing Parkinson’s Disease Mouse Model Repository.

The repository will house and distribute valuable MJFF-funded mouse models for use by the entire PD research community, removing a significant barrier to access. The mouse models created by Dr. Li and his colleagues, as well as other pre-clinical models developed with funding from MJFF, are already at JAX and ready for distribution.

“Working with JAX is one example of how MJFF is doing whatever it takes to speed drug development by getting the best research tools into as many scientists’ hands as possible,” says Sohini Chowdhury, associate director, team leader, Research Programs. “We can’t stand by and watch access issues slow down research progress.”



CJ Li (right)

Our Global Reach: Select List of Organizations with Active MJFF Awards in 2009

With up to 250 active awards in our portfolio at any given time, The Michael J. Fox Foundation is continuously engaging with Parkinson's disease researchers and thought leaders across the globe. Below are the organizations, companies and institutes that initiated new MJFF-funded PD research projects in 2009.

United States

Acadia Pharmaceuticals
Adolor Corporation
Alzheimer Research Forum
Amylin Pharmaceuticals, Inc.
ArmaGen Technologies, Inc.
Beth Israel Deaconess Medical Center
Biodesy, LLC
Brandeis University
Brigham & Women's Hospital
Brown University
Caliper Life Sciences (Xenogen)
Carmot Therapeutics, Inc.
Case Western Reserve University
Ceregene, Inc.
Chaperone Therapeutics, Inc.
Codman and Shurtleff, Inc.
Colorado State University
Columbia University
Coriell Institute for Medical Research
Covance
Creative Commons
Duke University
Emory University
Envivo Pharmaceuticals
Epitomics
FoldRx Pharmaceuticals, Inc.
Foundation for the National Institutes of Health
Harvard University
Henry Ford Health System
In Silico Biosciences
Indiana University
Intra-Cellular Therapies, Inc.
Invitrogen Corporation
Isis Pharmaceuticals, Inc.
Life Technologies
Louisiana State University Health Sciences Center-Shreveport
Massachusetts General Hospital

Mayo Clinic
Medtronic Neuromodulation
Montana State University
Mount Sinai School of Medicine
National Institute on Aging (NIA)/NIH
Northern California Institute for Research & Education
Northwestern University
Oregon Health & Science University
Parexel
Pfizer Global Research and Development
Purdue University
Retrotope, Inc.
Rockefeller University
Rush University
Saint Jude Children's Research Hospital
Satoris, Inc.
Sigma-Aldrich
Sign Path Pharma. Inc.
SRI International
Stanford University
Sun Health Research Institute
Targacept, Inc.
The Burnham Institute for Medical Research
The Institute for Neurodegenerative Disorders
The Jackson Laboratory
The Parkinson's Institute
The Salk Institute for Biological Studies
Thomas Jefferson University
University of Alabama at Birmingham
University of California, Los Angeles
University of California, San Francisco
University of Chicago
University of Cincinnati
University of Colorado at Denver & Health Sciences Center
University of Colorado Denver

University of Florida
University of Illinois at Chicago
University of Iowa
University of Pennsylvania
University of Pittsburgh
University of Rochester
University of South Florida
University of Southern California
University of Texas
University of Texas Southwestern Medical Center at Dallas
University of Washington
Virginia College of Osteopathic Medicine
Wayne State University
Weill Medical College

Australia

University of Sydney
University of Melbourne

Austria

University of Innsbruck

Belgium

University of Liege
Katholieke Universiteit Leuven
reMYND NV

Canada

University of Alberta
University of Ottawa
NeurAxon, Inc.
Toronto Western Hospital
Neurodyn Inc.

Denmark

University of Aarhus

France

University of Bordeaux
University of Nantes
INSERM
Toulouse University Hospital

Germany

InterMed Discovery GmbH
Max Planck Institute for Biophysical Chemistry
NextPharma
University Hospital Goettingen
Philipps University Marburg

Greece

Foundation for Biomedical Research of the Academy of Athens

Ireland

Opsona Therapeutics LTD

Israel

Hebrew University-Hadassah Medical School
Tel Aviv Sourasky Medical Center

Italy

University of Brescia
University of Padova

Spain

Universidad Autonoma de Madrid

Sweden

Lund University

Switzerland

Swiss Federal Institute of Technology Lausanne

Tunisia

National Institute of Neurology

United Kingdom

PRN
University of Dundee
University of Cambridge
GlaxoSmithKline
Imperial College London
Institute of Neurology
University of Newcastle upon Tyne

761
Number of grant applications reviewed by MJFF in 2009

Our Power to Convene: Select List of 2009 MJFF Workshops and Summit Meetings

In 2009, MJFF brought together more than 500 top researchers from academic and industry labs all over the world for approximately 40 conferences, summit meetings and workshops. These sessions catalyzed concrete action steps — new grant programs, funding for critical tools and resources, novel collaborations and other tactical interventions to move the best ideas forward faster.

“MJFF’s PD Therapeutics Conference is an essential meeting for PD drug development because of its focus on what really matters: presenting the highest-impact research ideas and compelling data. The goal is to streamline the process of aligning suitable partners and forging effective new collaborations.”

Franz Hefti, PhD,
Chief Scientific Officer,
Avid Radiopharmaceuticals;
Chair, PD Therapeutics
Conference 2010

ADDF Drug Discovery for Neurodegeneration, February 2–3

(Sponsored by the Alzheimer’s Drug Development Foundation)

Todd Sherer, PhD, vice president Research Programs, chaired a session on drug discovery and development for neurodegenerative diseases. Participants brainstormed potential solutions to issues including selection of research models, target validation and pre-clinical development.

Placebo Response Workshop, March 30

(Co-funded by The Davis Phinney Foundation)

Leading experts prioritized strategies for gaining a greater understanding of placebo effects in Parkinson’s to improve the design and testing of future therapeutics. The placebo effect — in which patients who receive an inert substance nonetheless experience some or all benefits of active treatment — has increasingly complicated the interpretation of outcomes from PD clinical trials, creating a significant hurdle to the development of new treatments.

Next Steps on Dyskinesia, June 3

World-leading experts on dyskinesia, including members of the Foundation’s Dyskinesia Working Group, assessed the status of various therapeutic approaches to alleviating this debilitating complication of long-term dopamine replacement therapy, and prioritized strategic next steps for MJFF and the field.

Third Annual PD Therapeutics Conference, September 30

Nearly 200 academic and industry researchers and business development professionals attended the only major scientific symposium exclusively focused on speeding PD therapeutic development.

Industry Strategy Session, October 8

Global leaders of biotech and pharmaceutical firms provided crucial feedback on MJFF’s efforts to engage industry to date. Participants also suggested next steps on de-risking Parkinson’s drug targets and explored additional ways that the Foundation could partner with industry to speed the development of transformative treatments and a cure for PD.

Partnering for Cures, December 1–3

(Sponsored by FasterCures)

Katie Hood, CEO, Debi Brooks, co-founder, and senior MJFF staff members participated in this first-of-its-kind meeting that brought together philanthropies, medical research foundations, and the biopharmaceutical industry in an effort to forge strategic collaborations key to the timely development of new medical treatments.

LRRK2 Summit, December 9

Global experts in PD genetics assessed the state of the field in LRRK2 biology and therapeutic development, evaluated MJFF and field-wide activities, and recommended actions for MJFF and the field to accelerate understanding of the role of LRRK2 and its translation into meaningful therapies for people with Parkinson’s disease.

535

Number of
researchers
convened by MJFF
for 40 strategic
meetings in 2009



2009 in Photos

1. Julianne Moore and Bart Freundlich.
2. Gregg Allman, Denis Leary, Sam Fox, Elvis Costello, Roger Daltrey, Michael J. Fox, John Popper and Steven Tyler backstage at "A Funny Thing Happened on the Way to Cure Parkinson's Disease."
3. Board member David Einhorn and his wife, Cheryl.
4. Amar Kuchinad, the top Team Fox fundraiser of 2009, after the NYC Half Marathon.
5. Board member Ryan Reynolds.
6. Twins Drew and Kyle Shackleton run the Chicago Marathon for Team Fox, qualifying for the Olympic trials in the process.
7. Michael J. Fox and Stevie Wonder at "A Sunny Thing Happened on the Way to Cure Parkinson's Disease."
8. Allison Maguire and Brian Grant (formerly of the Portland Trailblazers).
9. Rachael Ray and John Cusimano.



10




11



12



13



14



15



16

10. MJFF Board Chair George Prescott and his daughter, Cheri.

11. Board member Al Glickman with his wife, Judy, and Michael J. Fox.

12. MJFF Co-Founder Debi Brooks and Patient Council member Eugenia Brin.

13. David and Paige Glickman, hosts of "Sunny Thing" 2009, greet guests from the stage.

14. Tracy Pollan and Michael J. Fox.

15. Michael J. Fox, Martin and Helen Scorsese and Ronald O. Perelman.

16. Scott Fahey, Board member Doug Ostrover, MJFF CEO Katie Hood, Scott Williams and Board member Curtis Schenker.

2009 Donor Listing

In 2009, with the help of more than 56,000 individuals, corporations and foundations, The Michael J. Fox Foundation funded over \$39 million in Parkinson's research. We are deeply grateful for our donors' ongoing commitment to our mission to discover breakthrough treatments for Parkinson's disease.

This report lists those who honored us with significant contributions last year. Also listed are the many friends and family members to whom they paid tribute with their donations. It is in their name and spirit that we work with continued urgency toward a cure.

\$25,000,000 or more

The Brin Wojcicki Foundation

\$10,000,000 or more

Chris Sullivan*

\$2,000,000 or more

EMD Serono*

Kinetics Foundation*

Judith and George Prescott and Family*

The Edmond J. Safra Foundation*

The Doha S. Welbourn
Charities Trust

\$1,000,000 or more

Margaret C. Glosser Trust

Judy and Al Glickman/
Albert Glickman Family Foundation

Anne and Burt Kaplan*

Shackleton Family*

\$500,000 or more

Benaroya Foundation

Donny Deutsch*

Elan Pharmaceuticals, Inc.*

Great Investors' Best Ideas
Foundation/Michele and
Shad Rowe

*recognizes multi-year commitment



\$250,000 or more

Estate of Sam M. Anderson
 Cheryl and David Einhorn
 Lisa Piazza and David Golub*
 Greenlight Capital, Inc.
 Shannon and Mark L. Hart III
 Estate of John Christopher Kimmey
 Lazard Capital Markets
 Jean Patton 2005 Revocable Trust
 Carolyn and Curtis Schenker
 Karen Pritzker and Michael Vlock

\$100,000 or more

Anonymous (2)
 Estate of Helen Bennett
 Shanna and Jon Brooks
 Virginia Brooks*
 BTIG, LLC
 The James E. Cayne and Patricia D. Cayne Charitable Trust
 Joyce and Barry Cohen
 J. & F. Coody Inter Vivos Trust
 Cantor Fitzgerald
 Tracy Pollan and Michael J. Fox
 The Sol and Lillian Goldman Family
 Karen Finerman and Lawrence Golub
 John and Amy Griffin Foundation
 The Leona M. and Harry B. Helmsley Charitable Trust
 Holly Andersen, MD, and Douglas Hirsch*
 Rachel and Amar Kuchinad
 Dorothy L. Leshner Estate
 Allison and Casey Maguire
 Julie and Doug Ostrover
 Parkinson's Unity Walk
 Ronald O. Perelman
 Robert Pritzker
 The Pumpkin Foundation/Joe and Carol Reich
 Mrs. Edmond J. Safra
 Carl and Ruth Shapiro Family Foundation

\$50,000 or more

Anonymous (3)
 Bachmann-Strauss Dystonia and Parkinson Foundation, Inc.
 Sara and Kate Bloom Fund
 Boehringer Ingelheim Pharmaceuticals, Inc.
 Claire and Jason Capello
 Barbara and Julian Cherubini
 Estate of Beryll Deming
 French American Charitable Trust

The Greater Kansas City Community Foundation & Affiliated Trust
 Carolyne and Edwin Levy
 Jennifer and Marc Lipschultz
 Joella and John Lykouratzos
 The Mann Family Foundation
 Zella M. McClure
 The Miller Family Foundation
 Edna May Minnick Estate
 Newman's Own Foundation, Inc.
 Oak Creek Foundation
 Pershing Square Capital Management
 Prince Charitable Trusts
 Caroleen Feeney and Richie Rothenberg
 Solvay Pharmaceuticals
 Katherine Farley and Jerry I. Speyer

\$25,000 or more

Anonymous
 The Jeffrey A. Altman Foundation
 Bloomberg
 Julie Bowen and Scott Phillips
 Estate of Ruth Carter
 Ellen Hooker and Joseph Cassano
 Morgan Management — Robert Morgan, Robert Moser, Chase Chavin and their families
 Sonya and Dev Chodry
 Stuart Clifton
 Steven and Alexandra Cohen Foundation
 Camille and Michael Costa
 DEARS Foundation, Inc.
 Deutsche Bank Securities, Inc.
 Dillard's, Inc.
 Jane and Rudolph DiNunzio
 Norma Doering*
 Eva Andersson-Dubin, MD, and Glenn Dubin
 Valerie Feigen and Steven Eisman
 Richard H. Fitzgerald
 Lee Fixel
 Jay Goldman
 Susan and Kim Henry
 Buddy and Edna Herring
 Armin & Esther Hirsch Foundation
 Marjorie and Robert Hirschhorn
 Ionic Capital Management
 Sonia and Paul T. Jones
 The Kellar Family Foundation
 The Lauder Foundation
 Douglas Liebhaufsky and Wendy Gimbel Charitable Fund
 Margaret Munzer Loeb and Daniel Loeb
 Merck
 Meredith Whitney Advisory Group
 Mirken Foundation
 Catherine and John T. Morse
 Park Foundation
 Pfizer, Inc.
 Julie Turaj and Robert Pohly
 Rawley Foundation
 Joshua Rosman
 Carolyn and Marc Rowan
 Rick Rucker — Lawrence County Parkinson's Association
 Elizabeth and Scott Schefrin
 Lisa Rotmil and Alex Schmelzer
 Hilary Bates and Jerome Simon
 The Melvin and Bren Simon Charitable Foundation
 Winthrop H. Smith Family Foundation
 Anne-Cecile Engell Speyer and Rob Speyer
 Suwyn Family Foundation*
 Mildred E. Swanson Foundation
 Teva Pharmaceutical Industries Ltd.
 Maida and Ralph W. Tyron
 Ullmann Family Foundation, Inc.
 Viacom International, Inc.
 Amy and Fred Weiss
 Kimberly Williams-Paisley and Brad Paisley

\$10,000 or more

Anonymous (8)
 Lisette Ackenberg
 Allen & Company
 Alpha Search Advisory Partners, LLC
 Ammon Foundation
 Avenue Capital Group
 Barclays Capital
 Sylvia M. Becherer
 Amanda Peet and David Benioff
 Melissa E. Benzuly
 Andrea Billhardt
 Eric Blecker
 Rita and Irwin Blitt
 Christina Bloom
 Margo and Mitchell Blutt
 Donya and Scott Bommer/ SAB Capital Management
 W. L. Lyons Brown Foundation
 William O. Burnett Foundation
 Patrice M. Campbell
 The Carmen Foundation
 Stephanie and Wayne Caron
 Donna and Jake Carpenter
 Susan and Nicholas Carter
 Stephen and Carolyn Chase
 City Arts & Lectures, Inc.
 Close To A Cure
 Nancy and Samuel D. Colella
 The William E. Connor Foundation, Inc.
 Consolidated Anti-Aging Foundation
 Cossette Communication, Inc.
 The Anthony M. Cotoia Foundation, LLC.
 Basil J. Coughlan II
 Rachael Ray and John Cusimano
 Norah and John Daly
 Eleanor and Peter Daniels
 Josefina Diez
 Mr. and Mrs. Edward J. Dobbs
 Cheryl and Blair Effron
 Craig Effron and Company
 Thomas and Jeanne Elmezzzi Private Foundation
 The Emerson Hermetic Motor Division
 Lois and Richard England Family Foundation
 The Ettleman Family Fund
 Mary Kay Fitzsimmons
 Dr. Marsha Heinke and Dr. Lawrence Forthofer
 Julianne Moore and Bart Freundlich
 Friedman Family Foundation
 Orrie M. Friedman Charitable Fund
 Christen C. & Ben H. Garrett Family Foundation
 Jayne Godfrey
 Stephanie and Robert Goldstein
 Meg and Bennett Goodman
 Brian Grant
 The Grateful Foundation, Inc.
 Ellyn and Michael Greenspan
 Jennifer and Bud Gruenberg
 Debbie and David Horn
 The Howard Family Charitable Fund
 Ann and Skip Irving
 ITSource Technology
 J.J.C.T.M. Foundation
 The Rona Jaffe Foundation
 Patricia Jehle
 Jet Capital Management
 The Robert Wood Johnson Foundation
 Eleanor Francis Nelson Jordan
 JP Morgan Chase Foundation
 Ellen Francesca Judge
 Drs. Julie and Scott Kalniz

*recognizes multi-year commitment

MJFF Becomes a Registered Canadian Charity

In 2009, The Michael J. Fox Foundation became a registered, tax-exempt charity in Canada, making all donations to MJFF from Canadian residents tax-deductible to the full extent of the law. Said MJFF founder and Canada native Michael J. Fox, “We have always been fortunate to be on the receiving end of a steady outpouring of Canadian support for our efforts to speed a cure for Parkinson’s. Canadian researchers have also been actively involved in our scientific agenda since our earliest days. It’s tremendously meaningful to me that our Foundation is now an officially registered charity in my home country.” The Foundation is grateful to these Canadian friends for their generosity in 2009.

Doris Adams	J. Moffat Dunlap	Mount Allison University	Rivers Reid Ranscombe
Aerial Communications Group, Inc.	Emblem	Steve Klassen	RBC Dominion Securities, Inc.
Apotex Foundation	EnerSpectrum Group	KPMG LLP	RBC Foundation
James William Ashcroft	Peter Farmer	Krembil Foundation	Heather M. Regent
Steve Atkinson	David Feldman	Roger D. Lace	Andy Renton
Andy C. Barrie	Franmed Consultants (1993), Inc.	Esther Lamoureux	Natalie Rosen
Michele Bebis	Fraser Milner Casgrain LLP	Nancy Lang	Sage Investments Limited
The Bitove Foundation	Paul A. Fredricks	Christine Leslie	The Sauder School of Business
Kathy Blackmore	Dr. Bruce V. Freeman	Paul F. Little	Rob Scheffley
Francois Bourret	Stanley Fularczuk	Andre Longpre	Ianna Selkirk
Michael Bregman	Galin Foundation	Matthew MacGregor	Hemant Sharma
Canaccord Capital Corporation	Sheldon Garfinkle	Janet Mackinnon	Erin Sheard
Claire and Jason Capello	GiveMeaning Foundation	Rosa MacLeod	Ferne Sherkin-Langer
Nina Castle	Richard Goldberg	Malcolm Marcus	Dr. Shaun Singer
Yves Chabot	Geoffrey Gouinlock	Joyce Mason	Gale Single
James Chmiel	Chris Grannan	Soania and Arun Mathur	Mitra Singh
Church Street The Place for Steak	Griffiths McBurney Canada Corp	Leslie McBeth	Dr. Paul Slavchenko
Virginia Cirocco	Dr. Milan Gupta	Cheryl and Rob McEwen	Michael Spanier
Catherine E. Clark	Andrew S. Haibeck	Mike McPartland	Maureen Squibb
Judith L. Cohen	Nancy M. Holland	Joseph M. Meaden	St. Joseph Communications
Roberta R. Cooper	John C. Hamilton	Medtronic of Canada Ltd.	Simon Stanlake
Sherry S. Cooper	The Poul Hansen Family	Merz Pharma Canada Ltd.	Michael L. Stein
Bruce Cornell	Tennys J. Hanson	Henry S. Mews	Ronnie Strasser
Cossette Communication, Inc.	William H. Hatanaka	Minuk Construction & Engineering Company	Carol Grant Sullivan
Creative Colour & Communications, Inc.	Linda Elizabeth Hazen	William Moll	Charles W. Tellett
Dahlman Rose & Company, LLC	Endowment Fund	Annick Mullen	Telus Corporation
Eleanor and Peter Daniels	Adam Hegge	John Mullen	Levino Tittaferante
Jennifer D'Aoust	Paul Higgins	National Bank Financial Group	Toronto General & Western Hospital Foundation
Jamin Davies	Jane Hill	Kristy and Eric Nuttall	Bruce Towler
Lisa de Lusignan	Susan E. Hillary	Thomas J. Obradovich	Caird Urquhart
Marc C. Deslongchamps	Bethany Hoffman	Osler, Hoskin & Harcourt LLP	Deb Voorheis
Distort, Inc.	Beth S. Horowitz	Dr. Shekhar Pandey	G. Wesley Voorheis
Heli Donaldson	Minnie Horowitz	Parkinson Society Canada	Deborah Walter
Karin and Christopher Downie	HSBC Bank Canada	Paul Pathak	Michael A. Wekerle
Downtown Fine Cars, Inc.	I.P. Rosati Holdings Limited	Joanna Pedersen	Andrea Witzel
Dr. Thomas Morton Medicine Professional Corporation	JTB International (Canada) Ltd.	Rebecca Philps	Robert D. Wortzman
Rupert J. Duchesne	Justine Blainey Wellness Centre	Louise Poelzer	York University Foundation — Foundation de l'Université York
	Jonathan Kaide	Dr. Mani Raman	
	Kalex Equipment Services		
	Dr. Anil Kapoor		
	Dr. Sunil Kapoor		



\$10,000 or more (continued from page 23)

The Kay Family Fund
The Keyser Family
Patricia Stonesifer and
Michael Kinsley
The George Kress Foundation, Inc.

Jenny Hewlett and
Adam J. Kutas
Martha Lam
Amalia and Peter H. Lucas

Tami and Fredric Mack
Janet and Tim Maher
Soania and Arun Mathur
Maverick Capital Foundation
Howard McClure

Trish McEvoy
Dennis M. McIntosh
Barb and Terry Meguid
Kalpana Merchant

Norman A. Merollis
Patricia and Wallace Mersereau
Bette Midler
Sandra Milken
Marilyn Muir

Nationwide Foundation
Nancy and Bruce Newberg
Kim and Richard Nicely
Jennifer and Sean O'Neal

Parkinson Association of
Northern California
PCG Corp. 1

The Geraldine and Eugene
Pergament Education Fund

The Pioneer Fund
Estate of Marjorie D. Pippie
Corky and Stephen Pollan

Jill and Mark Rachesky
Bobbi and George Rainwater
Debbie and Rob Rodin
Allen Rosenberg

Beatrice Rosenthal
Georgina and Alan Rothenberg
Pablo Salame

Julie and Gary Salomon
Estate of Eileen R. Salter
Pam and Jon Scarborough

Francesco Scattone
Schaner & Lubitz, PLLC

The Edward I. Seagraves Fund

William and Jacqueline Shaw Family
Foundation

Patti and Martin Shenkman
and Family

Jill and Bill Shepherd
Elsa and Stanley Sidel

Jean S. Smith Revocable Trust

Sheila and Tripp Smith
Judith Smolin
Henry Spector
Corey Hajim and Jim Sperber
Stupell Foundation, Inc.
Michelle and Howard Swarzman
Leah and Steven Swarzman
Jack Taylor
Levino Tittaferante
Sophia Tomich Living Trust
Karin and Kenneth Travis
U. S. Bank, The Private Client Reserve
United Talent Agency
Leslie and Bill Vollbracht
Remer and Donald Waguespack
I. Waldbaum Family Foundation
Reid and Stacey Walker
Estate of Margaret M. Wall
The Walsh Family
Dr. Brent and Terry Weinberger
Katie B. Whorton
Bill and Sara Wilkins
Joan B. Wilton
Joe and Carol Wishcamper Fund
Daniel Wolf
Barbara and Stanley Zax

\$5,000 or more

Anonymous (3)
Nina Abrams Fund
Acadia Pharmaceuticals
Sigma Advanced Genetic
Engineering (SAGE) Labs
Kenneth Aidekman Family Foundation
AK Steel Foundation
Nonie and Larry Akman Fund of
the Community Foundation for the
National Capital Region
Paul B. Albritton
ALL TRI, Inc.
Jack and Sylvia Altman Foundation
Amicus Therapeutics, Inc.
Marlene and Daniel Arbess
Karen and Gregory Arrese
Babior Foundation
Lino J. Bailo Trust
Lois Barnard
Mario Batali
Elaine J. Beresh
Robin Berman, MD, and
Ed Berman
Biotechnology Industry Organization
Debra and Leon Black
Dan & Merrie Boone Foundation

The Boston Foundation
Mark J. Boujoukos
Eugenia Brin
Ms. Leila Kamal and Mr. Andrew
Brockway
Brokerage Unlimited Incorporated
Nicole and Brad Brooks
Debi and Jeff Brooks
Brown Charitable Foundation
Bruno-Shayegani Family Foundation
Paul Chan
John Chuck
Bruce Cohen
Gloria Cohen
Stephanie and Chase Coleman
Toby Cooper
Courageous Steps for Parkinson's
CSRA PD Support Group Walkathon
Dawn and Edward D'Alelio
Larry and Anne Davis
Gavin De Becker
Jill and Jeffrey Degen
James G. DelMauro
Mark Dickstein
Ms. Valerie A. DiFebo and Mr. James
D. Byrne

The Donegan-Burns Foundation
Mary E. Dooner Foundation, Inc.

Hillel Drazin
Donald D. Drobny
Catherine Boshaw and
Doug Edlund
Drs. Jane and David Eger
Amelia Feinburg
Firman Fund
Bill Fischer
Fowey Light Fund, Inc.

Fox Family Foundation
Pamela and George J. Fox
Lynn and Joel Frank
Joyce A. Friedman

Ron and Linda Galowich
Ellen Gaslow
Kathryn and Oliver Gill

GiveMeaning Foundation
Paige and David Glickman
Deborah and Brian Gottlieb

The Tom and Bonnie Grace Family
Foundation

Wally and Charlie Graham
Mr. and Mrs. Alan C. Greenberg
Jeff and Mei Sze Greene Foundation
Laura and William Gruy
Eugene Gurkoff

Jeffrey Hamer
Jonathan M. Harris Family Foundation
Kathy Harris
The Claudia Hearn and Edward Stern
Foundation
Wandy and William Hoh
James Holmes
Judith and Michael Hooffstetter
Benjamin and Jessica Hoyer
Jesse Itzler
Lisa and Lamar Johnson
Mr. and Mrs. David O. Jones
Candace Leeds and Ed Katz
Joy and Eric Kaye
Mary and Richard Ketchum
Mary Kilfoy
Kathryn and Richard Kimball
Paul Klinger
Marjorie and Russell Knauer
Mrs. William T. Knight, III
John & Evelyn Kossak Foundation, Inc.
Nyssa and Bill Kourakos
Kramer Levin Naftalis & Frankel LLP
Guymon Casady and Eric Kranzler
Christina and Barry Kringstein
Esther Lamoureux
Linda and Alan Landis
Lark Hall Films
Blanche & Irving Laurie Foundation
Dr. and Mrs. Lawrence E. Lee
Lee Family Fund
The Leibowitz & Greenway Family
Charitable Foundation
Gloria Levine & Harvey Levine
Charitable Foundation
Kathy and Michael J. Lewis
Light Of Day Foundation
Holly and Jonathan Lipton
Deborah and Jim Long
M & T Trust
Robert Macklin
Ellyn and Michael Maguire
Roxanne Majka
Make It Possible Foundation, Inc.
Marla Meg Gordon, Kornstein Veisz
Wexler & Pollard, LLP
Mary and Robert Mandell
Gary Marks
Kathleen Kennedy and Frank Marshall
John and Maude Matouk Charitable
Foundation
Mayer Family Foundation
Cindy and Mike McConnell
Helen M. McGinn

continued on page 26

\$5,000 or more (continued from page 25)

Stefanie Meisel and Scott Macklin
 Jodi and Kenneth Meister
 Merkle Response Management Group
 Leo Miller Family Foundation
 Estate of May Moore
 Carolin Moran
 Elizabeth Moran
 Donald Mullen
 Beth and James Kevin Murray
 George M. Murray, III Revocable Trust
 John P. Murrin
 Muskin Family Foundation
 The Andrew Nagel and David Brodsky Fund
 Tracy and Larry Nagler
 Robert D. Nankervis
 Jack Nash
 Joyce and William Niles
 Julie and Scott Ohlman
 Marlene Osthoff
 Mary Anne and Jim Ostrenga
 Leslie B. Otten
 Parkinson's Resources of Oregon
 Denise and Donald Paulus
 Barbara H. Pekow
 Peterson Foundation For Parkinson's
 Justin Pines
 James and Virginia Pitts
 Lea and Barry Porter Fund
 Mrs. Jeanne F. Coleman and Mr. Lawrence F. Portnoy
 Dr. and Mrs. Mukesh Prasad
 The William L. Price Charitable Foundation
 Stephen P. Rader and Family
 Bradley L. Radoff
 Linda and Richard Reiss
 Katherine and Michael Renoff
 The Rhodes Foundation
 Edward Robinson
 Sharon and Scott Robinson
 William Rosenbaum
 Shani and Doug Rothschild
 Royal Capital Managment
 Samaritan Fund
 Harriet Samuels
 Jennifer M. Schneck
 Manuel Schneider Living Trust
 Cheryl and David Schreiner
 Lynda Brecke and Rick Schwartz
 Mark Seliger
 The Shack Sackler Family
 Frank Selvaggi and William Shea
 Jack Shenkman Trust

Signature Bank
 Mr. and Mrs. Donald Simon
 Mary and Robert Slaughter
 Sony Corporation of America
 Tina and Mark Stacy
 Carol and Jim Storm
 Jennifer and John Streit
 Pamela and Jeffrey Swartz
 Tamkin Foundation, Inc.
 Priscilla and Curt Tamkin
 Carol and Melvin Taub
 Teco-Westinghouse Motor Company
 Kent M. Thornbrugh
 Peggy Segal and David Topper
 Mr. and Mrs. Charles Tyler
 Susan and Donald Ullmann
 Charles Vosmik
 David M. Wah
 Dr. and Mrs. John R. Walch
 Beth and John Weaver
 Melvyn and Barbara Weiss Family Foundation, Inc.
 The Harold Wetterberg Foundation
 Carole and Rick Wiederhorn
 Teresa L. Wilde
 Janice and Alan Wingo
 Mary A. Wintzer
 Robert Zemeckis
 Ruth Zinar

\$2,500 or more

Anonymous (3)
 Susanna Lachs Adler and Dean Adler
 Geraldine and Harold Alden
 Steve A. Alexander
 Mary and Edward Allen
 Sophie and Alan Alpert
 Alseres Pharmaceuticals, Inc.
 Carrie and Robert Andalman
 The Stanley and Blanche Ash Foundation
 Anthony Baer
 Baron's Fabrics, Inc.
 Barbara S. Baxter
 Bayview Foundation
 Carolyn and Don Berger
 Evelyn and William Bernstein
 Duncan Blair
 Charles J. and Brenda Block Family Philanthropic Fund
 Lisa Boom
 Joan Borinstein
 James H. Breay
 Tyler Burke

Lawrence Butler
 Patricia and Alfred Byrnes
 California Jurisdictional Convention
 Linda and Alexander L. Cappello
 Jock Casasus
 Ruth Jones Casey Foundation
 Ceregene, Inc.
 Yves Chabot
 Linda and Bernard Chalfin
 Charina Foundation, Inc.
 J. Dawn and Mark Christman
 Church Street The Place for Steak
 Stacy and Richard Clark
 William Connelly
 Roger Cooper
 Corn Products International
 William Curtis
 Kimberly Ann Davis
 Mr. and Mrs. Maged Diab
 Tim Disney
 Silvia and Kevin Dretzka
 Sheryl Eberhardt
 Linda and Richard Ellis Family
 Kathy Emmerson
 Nell Everman
 Helen Ficalora
 Jean and Richard Fiesinger
 Michele and Drew Figdor
 Toby and Oscar Fitzgerald
 Debby and Lou Flancbaum
 Rayma and William Flint
 Nelle and John Fortenberry
 Mark Frey
 Sharon N. Freytag
 Joan Frost
 Lori and Simon Furie
 Ronald Garriques
 Alan Gates
 Beverly and Herb Gelfand
 Laurel and George Gerhat
 Robert Gersh
 The Glen Oaks Philanthropic Fund
 Elaine and Brenner Glickman
 Mindy and Jeff Glickman
 Lisanne and Howard Godnick
 Dawn and Jim Goldfarb
 Nancy Jane and Mark Goldston
 Estate of Rafael Joseph Gonzalez
 Camille E. Granato
 Ryan Grant
 The George & Reva Graziadio Foundation
 Vicki and Michael Gross

Adele and Mark Hart, Jr.
 Nancy Hausman
 June M. Haverly
 Sharra L. Haynes
 Health Advances, LLC
 Sheila and Jonathan Herr
 Daniel Herz
 Tom Heymann
 Craig Hill
 Mark Hoffman
 Katie and Phil Holthouse
 Rusty Holzer
 Katie and Aaron Hood
 Austin Hope
 David Hornkohl
 Pat and Shirley Howe Fund
 Jill and Stuart Hurwitz
 Leslie Weisberg and James Hyman
 IBM Corporation
 Illinois Shotokan Booster Club
 International Precious Metals Institute
 Dr. Brenda M. Ivker, PhD
 J.C. Kellogg Foundation
 Deb and Tim Jacobus
 Jamakepe Foundation
 The Joelson Foundation
 Harry Johnson
 Josflo Corporation
 JTB International (Canada) Ltd.
 Dora and Neil Kadisha
 Tigraw Kastenbergl
 Seow K. Kek Thay
 Elyssa Kellerman
 Michael H. Kelson
 Harris and Eliza Kempner Fund
 Kings Oil Tools Incorporated
 Natalie and Brian Kirkdoffer
 Bonnie and Bradford Klein
 Michael A. Kolodny
 David A. Kovner
 Joanne and Roger Kozberg
 Judy and Joseph Lamastra
 Lambert Family Foundation
 Jeffery R. Leake
 Phillip E. Ledin
 Wallace R. and Bernice E. Leslie Memorial Fund
 David and Julie Levine Family Philanthropic Fund
 Norman H. Levine
 The Jack R. Linsky Foundation
 Marshall and Carolyn Litchmann
 Susan and Preston Lowe



The MJFF Legacy Circle

The Legacy Circle honors friends who support the Foundation's work through bequests or other planned gifts. While MJFF's mission has always been to put itself out of business by curing PD, planned gifts provide a major, long-term funding source that we can both plan around, and leverage immediately, to accelerate high-impact research.

Matthew MacGregor	Anonymous (8)	Estate of Martin Nash	Gail Reeves
John Magnuson	Sylvia Marie Becherer Revocable Living Trust	Estate of Don and Ruth Palmer	Judith Snow Reidel
Anthony Magoch	Richard Belman	Estate of Jean Patton	The Elfrieda Remlinger Revocable Living Trust
Joe Marinucci	Lorri Boetto	Estate of Marjorie Pippie	Thomas Sabourin
David & Susan Martin Foundation	Virginia Brooks	Estate of Melvin Rauch	Karen Schneider
Joel McCleary	Jock Casarus	Estate of Marjorie Richards	Manuel Schneider Living Trust
Anne and James McCoy	Cal Chadwick	Estate of Lucile Traeger	Sean Sidway
John L. McHugh Foundation, Inc.	Frederick C. Colton	Estate of Melvin S. Zuckerman	Henry F. Spector
McKesson Corporation	Frances Reser Coody in memory of John Lester Coody	Janet and Robert B. Ettleman	Dorothy Strauss
Carole Joyce McNeil	Anne and Larry Davis	Jeff Evans	The Gilbert Strong Trust
Christopher L. Medina	Rudy and Jane DiNunzio	Barbara Folender	The Sutherland Family
Clent Mericle	Estate of Sam Anderson	The Donald and Martha B. Geibel Trust	The Teitelbaum Family Trust
Elizabeth and Leslie Michelson	Estate of Lisa Susan Baricelli-Kureen	Margaret C. Glosser Trust	The Sophia Tomich Trust
Lee Middlekauff — Citi	Estate of Helen Bennett	Peter Gonsalves	The John D. Turkel Revocable Trust
Debbie Minard	Estate of Ruth Carter	Juan Griego	Alessio and Flora Ventura
Brent A. Miner	Estate of Alma Chitwood	The Frederick W., Norma G., and Janet L. Grill Family Endowment Fund	Margareth M. Wall
Beni F. Monaco	Estate of Catherine Ciocca	Andrew S. Grove	Dr. Brent and Terry Weinberger
Mariann and Carl Morales	Estate of Diane Mae Clark	Thomas K. & Yvonne G. Hanes Charitable Remainder Trust	Elizabeth H. Weinraub
Shelley Olson and Ramiro Moreno	Estate of Josephine M. Cretnik	Richard Henriksen	The Dotha S. Welbourn Charities Trust
Mary and Warren Myer	Estate of Henry Czerwec	Lee Herman	The Charles C. White Revocable Trust
NBSC	Estate of Beryl Deming	Mary Hopkins	Kathryn P. Wright
Wesley & Julie Nichols Family Foundation	Estate of Marjory S. Fellman	The Hoover Family Charitable Remainder Trust	Yacuone Living Trust
Northrop Custom Metal, LLC	Estate of Rafael J. Gonzalez	Judy and Charles A. Huss	
Nancy J. Novick	Estate of Richard Gorman	The Grace Richardson Jones Trust	
Earline Arnold and Deryck Nuckton	Estate of Iva Pauline Hancock	Eleanor Frances Nelson Jordan	
Victoria and Ryan O'Hara	Estate of Pollyanna Herrell	The Jerry Katz Trust	
Doris and Thomas Parry	Estate of Helen Hoskin	Rev. Dolores K. Kimsey	
Diane M. Pattee	Estate of Jack Kellogg	Rose Krieger	
Amy and Joseph Perella	Estate of John Christopher Kimmey	Jim and Deborah Long	
David Phillips	Estate of Dolores E. Kossak	Sally and Andrew Lorenz	
Sylvia L. Polen	Estate of Louis Krieger	Robert G. Lusk	
Judith Belzer and Michael K. Pollan	Estate of Raymond H. Lake	The Edmund Ernst McClure Trust	
Marla and Dean Provost	Estate of Dorothy Leshner	Elizabeth Murphy	
Pugliese Family Charitable Fund	Estate of Deb Lipton	Karen Oliver	
Larry F. Randall	Estate of Byron Mavrelis	The Margaret Paul Trust	
Rainier Investment Management, Inc.	Estate of Geraldine McMillan	John Richard Randall	
Jennifer Saul and Stephen Rich	Estate of Edna May Minnick	Larry Randall	
The Philip W. Riskin Charitable Foundation	Estate of May Moore	Estelle Randolph	
Mr. Richard G. Robb Jr.	Estate of Sidney Kanz Morgan		
Rocking For Parkinson's Disease Research Foundation, Inc.			
Larry Roi			
Michael R. Romanowski			
Lawrence Ruben			
Thomas J. Sabourin			
Susan G. Salerno			
Kenneth R. Salling			
Vik and Margarita Sawhney			
Brian, Maire, Aidan and Maeve Schirf			
Schwab Charitable Fund			

If you have made estate plans that include MJFF and would like to be listed as a member of The Legacy Circle, please call Karen Leies at (212) 509-0995, ext. 269.

\$2,500 or more (continued from page 27)

Charles Scott	Brenda and Robert Aiken	Don C. Bedell	Jared Brimfield
Jeff Seabold	Roger E. Ailes	Nancy and Michael Beebe	The Judy & Bernard Briskin Fund
Michele and Kenneth Seim	Alaska AFL-CIO	Dr. Holley A. Belch	Lynn A. Brody
Kevin Sheehan	Andrew Albert	Gerry B. Belling Philanthropic Fund	Ellen and Peter Brody
Robert Sholty	Eduardo Alcocer	Peter Benedek	John F. Brown
Glen and Amy Siegel	Michelle B. Alifanz	Michael J. Bensing	Lisa and Steve Brown
Sills Foundation, Inc.	Robert Allard	Alfred K. Berg	Diana Browner
Linda and J.R. Sims	Andrew Allen	Susan and Adam Berger	Keith N. Browning Family Foundation
Rita Sklar	Julie and David Allen	Michael Bernstein	Beatrice Bruce
Jude and Joseph Smith	Jean and Harold Allen	Nancy and John Bertino	Christian Bruckner
Maureen and Glen Smith	Jodie and George Allen	Jo Anne and David Beschere	Sandra and Peter Bruhn
Delores and Isaac Soffer	Donald Allman	Jo-Anne and Richard Bilotti	Horst Brunner
Solomon Family Foundation	William E. Alt Charitable Fund	Harvey Bird	Mr. and Mrs. Steven C. Bryant
Sound Sight Technologies, Inc.	George Amandola	Joann M. Bisto	Janis and Wiley Buchanan
South Valley Civic Theatre	Amedisys Incorporated	Kathy Blackmore	Dana Buchman
Margaret P. Stevenson Foundation	American Endowment Foundation	Clarence and Sheila Blair	Beverly and James Buckley
Stolper Family Trust	Noni and Charlton Ames	Brad Blanchard	Kay and Matthew Bucksbaum
Rose and Richard Straeter	Nora Ammar	Barbara Blanchfield	Christine Bulawa
Lisa and Scott Stuart	Noah J. Anderson	Carol and Jim Blann	Otis Burdine
Summit County Parkinson's Support Group	Annette Andrade	Betty and Ray Blansett	Laura Kang and Paul Burkhead
Sundance Running Club	Anne and Joseph Andrew	Keith Block	Emily W. Burns
Ram Sundaram	Penny and Marion Antonini	Kristie and Steven Block	Burr and Forman, LLP
Dr. S. Jerome and Judith D. Tamkin	Nino Antuzzi	Christopher Bloise	Eugenia and George Burylo
Lisa and Steven Tananbaum Family Foundation	Sheldon & Carol Appel Family Foundation	Sandi and Jerry Bloomberg	Lloyd Byars
Tarshis Family Foundation	Dane Arden	Blue Bell Foundation	Celia M. Byrne
The Adam USDAN 2006 C.L.A.T	Jody and John Arnhold	John and Myrna Blume	The Harman Cain Family Foundation
The Kallis Family Charitable Foundation	Courteney Cox-Arquette and David Arquette	Dr. Maxwell L. & Florence C. Blumenreich Foundation	Brendan Callahan
Elizabeth and Dennis Tito	Sharon Asher	Boar's Head Brand Cassametta Provisions, Inc.	Carol S. Callahan
Gail and Richard Ullman	Audio Command Systems, Inc.	Bobbo Jetmundsen Foundation	Barbara and Roger Calvert
Meredith and Bryan Verona	Austin Community Foundation	Bock & Associates, LLC	Donald Cantway
Judy Wada	Auto Club Speedway/ Ms. Gillian Zucker	David Bohnett	Elaine and Elliott Caplow
Sally Washburn	Avad, LLC	Robin Bond	The Caravan Trust
Anne and William Washychyn	The Bacas Family Foundation	Joseph F. Boulos	Sandy Carey
Bradley J. Wechsler	Shae Baddour	Francois Bourret	Ian T. Carnathan
Norma and Ed Weinman	The Arnold F. Baggins Foundation, Inc.	Scott Boxer	Donna Carpenter
Linda and Patrick Welch	Lori Pollan and Allan Bahn	Tom and Leann Boyan	Cheryl and Steven Carver
Diane Wilsey	Anne B. Baker	Mark Boyd	Casey Family Advised Fund
Jan and Eddie Woods	Anne Elizabeth Baker	Norm and Linda Boyer	Peter Catalano
Billy Wooters	Pamela and Jesse Baker	Marcia and Dennis Brager	Dawn and Rocky Caullwine
Ken Wormser	Leslie and Buck Balkind	David S. Brammer	Barbara and Anthony Celeste
Mr. and Mrs. Wayne R. Zdenek	Paul C. Baria	Shirley and John Bandy	Centre Reinsurance
Jeannie and Terrence Lee Zehrer	John J. Barry	Dwight Brannon	Sara and Joe Cerrell
	Linda and Douglas Bartlett	Brenda and Robert Brantley	Jacquelyn Chandler
	Steve Barton	Braude Foundation	Robert T. Chang
	Michael Bartsch	David B. Breed	Charitable Foundation Trust
	Lee Bass	Janet M. Breedlove	Charitybuzz
	Mickey Bass	Daniel Brewer	Carol Chase
	Kathleen C. Bassi	Bricker & Eckler, LLP	Lance H. Chau
	Jerome Simon and Hilary Bates	Bridgewater Associates, Inc.	Alfred Checchi
	Beach Equities	Nicolas Brien	Marissa and Saj Cherian
	Lisa and David Beall	Devon and Peter Briger	Harry Chernin Foundation
			Helena Christensen
			William Christie

\$1,000 or more

Anonymous (18)
 Nancy and Colman Abbe
 Denise and Herb Abrash
 Jorge Acquaviva
 Aeroquip Credit Union
 Aggressive Heating, Inc.
 Agron, Inc.



Steven Chrzanowski	Michael De Jong	Elizabeth Ernst	Leslie and Morton Gerson
Chubb Corporation	Susan M. Delago	Atila Ertan	Steven Gerstung
The Chutorian-Semler Family Foundation	Gilles and Inge Dellaert	Drew Ertman	Lisa and Rick Giacco
Pamela Cincotta	Maureen and Robert Deloury	Judith and Irving Evall	Suzi and Steve Gilbert
Circle of Service Foundation	Paul D. Delva	The Evslin Family Foundation	Deborah and Donald Gill
Gary Cirilli	Robert Denlow	Tom Ezaki	Michael Gillen
Ciuni & Panichi Advisors	Sarah and Paul Densen	Ramsey Fadiman	Mike Ginsberg
Robert C. Clare	Charitable Foundation	Scott Fahey	GlaxoSmithKline
Claremore Club, Inc.	Ginny DePasqua	Fairwood Financial Services, LLC	Shirley Gleich
Erin E. Clark	Robert D'Eustachio	Darby and Jason Farmer	Kathy and Robert Glickman
Sacha Clark	Kimberly Dewalt	Peter Farmer	Justin Gmelich
Clayman Family Foundation	Charles Diamond	Stephen E. Farris	Stuart Goldblatt
Marlynn K. Clayton	Jerry Diamondstein	Fasnacht Family Foundation	Mitchell and Lenore Goldstein
Judi and George Clute	Richard Dickstein	Dennis R. Fay	Barbara M. Goodbody
The Coffee Bean & Tea Leaf	Linda K. Dieken	Bunny and Sy Feigenbaum	Sandra and Allen Gookin
Louise and Thomas Coffey	Jennifer and Royce Diener	Joan and William Feldman	Mark Gordon
Abe M. Cohen Family Foundation	Steve DiFillippo	William Fellows	James and Meg Gordon
Jeff Cohen	Distort, Inc.	Fidelity Charitable Gift Fund	Judith and Sheldon Gordon
Dena and Steven Cohen	Don P. Dizon	Albert L. Fierro Sr. Charitable Foundation	James and Penny Gorman
Mr. and Mrs. S. Michael Cohen	Jody Dobrowski	Esther Baird and Stanley Fimberg	Irwin Gottlieb
George F. Cole	Joseph Dorsey	Magdalen Fisher	Thomas Gottlieb & Carol Kirsh Family Fund
Tracey and Adam Collins	Karen and Christopher Downie	Peggy and Dick Fitzgerald	The Gould-Shenfeld Family Foundation
CommerceNet	Clorinda R. Driscoll	Andrew Fitzgerald and Richard Fitzgerald	The Grace Jones Richardson Trust
Competition Corvette Association Incorporated	Jesse Du Bey	Timothy Fitzgibbons	Grand Temple #15 Pythian Sisters NYC
Compulink Business Systems	Patty and Howard Dubin	Ilene and David Flaum	Grange Kitchen and Bar
Susie and Butch Conen	Michael Dubin	Maria and Raymond Floyd	Alison and Andrew Gratz
John C. Conwell	Stephanie and Brian Dubinsky	The Ellen M. and Lawrence B. Floyd Family Foundation	Mr. and Mrs. Bennett Grau
Cooper Sheet Metal	James M. DuBois	Deirdre Flynn	Erica and Kenneth Grau
Debi Corbin	Patrick and Mary Dunleavy	Kenny Foo	Marisa and Edward O. Green
Anita Cosgrove	Dr. and Mrs. Paul P. Dunn	The Ford Family Foundation	Zoe and Steve Green
Laurel and John Cravens	Marsha and Anthony Durniak	Mary Ann Forman	Theodora and Robert Greenbaum
Mrs. Joan Creedon	Marvin and Jean Durning	Amy Foster	Sandy and Irwin Greenberg
Jeanne and Peter Crisci	Kris Dworkoski	The Connie Frank Foundation	The Martin B. Greenberg Foundation
Jeremy R. Crisup	Robert Dworkoski	Bruce and Kipp Freeman	Sheila Greenberg
CWS Apartment Homes, LLC	The Dyer Family	Katherine Frekko	Nancy S. Greene
Louis Dahan	Carole and David Ebner	Andrew and Brooke Friedman	Greenlight Foundation
Dalio Family Foundation, Inc.	Stanley Ebner	Edna Frigo	Sherwin Greenwald
Jan Dallam	The Economist Newspaper	Judge Hilda R. Gage	Donald E. Greenway
Kumaran Damodaran	The Edgecomb Foundation	Roy Gagnon	Sharon Gregorcyk
Diane Danakas-Discoe	Adele Eger	William Gaine	Edward W. Griffin Memorial Fund
Katherine and Costa Darras	Ronald Eger	Jane and Robert Gallagher	Clark Grimm
The David Family Foundation	Marty and Dale Ehrenreich	Patricia and Lawrence Galloway	Glenn Grossman
Nancy and Russell Davidson	Mitzi & Warren Eisenberg	Gans-Mex, LLC	Deborah and Allen Grubman
Ellen and Gary Davis	Family Foundation	Richard Garber	Kevin Gruver
Joey Davis	Mrs. Ethel Eisenberg	Ken Garschina	Charlotte and Larry Gustavson
Scott Davis	Bruce W. Elder	Jerry Geldernick	Robert Haber
Kathryn and Stuart De Haaff	Gail and Jim Ellis	Mary and Peter Gens	Cindy and James Hadaway
Elizabeth de Ramel	Lisa and Christopher Engel	Pat and Charles Genuardi	Barbara and Ed Haddad
Dick Deery	Charles Engelke and Laurie White Fund	George Weintraub & Sons, Inc.	Mallory and Peter Haffenreffer
Karen and Carl deGraaf	Richard England	Marilyn Gerber	Lia and Bruce Hager
David Deibel	Joann and Wayne English	Joan L. Germany	Ginger and Larry Hahn
	Rodney English		Amy and David Halliburton
	Ross Epstein		

continued on page 30

\$1,000 or more (continued from page 29)

Halperin Foundation	Robert Holo	Stephen and Laurie Kafka	Yvette and Roger Kotch
Jeremy Halpern	Samuel and Hannah Holzman Trust	Kahn Foundation	Selma and Eldon Koznek
Don and Mary Jane Hamaker	Honey Farms, Inc.	Robert J. Kahn Foundation	Mitchell Kramer
Rodney N. Hamilton	Keith A. Hoover	Richard Kaminsky	Elaine Kranich
The Hamilton Foundation, Inc.	Mary Hopkins	G. Kanda	Seth Krauss
William Hamm	Joan Hotchkiss	Thomas Kandel	James Kress
Andrea and John Hampshire	The Mary L. House Charitable Gifts	Stephen F. Kaney	Carole and Hal Kroeger
Rita Wilson and Tom Hanks	Lina Hu	Sally and Paul R. Kanin	Lisa and Clyde Krogh
Rochelle Hanna	Hub International Northeast Limited	Carol G. Kaplan	Beth and Williams Krumbein
Stan Hannah	Carol and Frank Huber	Ruth and Jess Karter	Kevin M. Kruszenski
Trish Hanson	Leane and Gerald Huchital	Karen Katen Foundation	Kucera Family Foundation
Harbor Casino Bar Restaurant, LLC	Paul Huchro	The Jerry Katz Trust	Jon Kully
Eric Hardesty	Hudson Housing Capital, LLC	Beth and Brett Kaufman	David Kurti
Judy and Joseph Harding	The Huisking Foundation, Inc.	Andrea Kay	Randy and Brian Kwait
Susan and Richard Hare Family Foundation	Derris and John Humphrey	Lauren, Dave, Brady and Reagan Kay	Lake Forest/Lake Bluff Junior Women's Club
Ethel and Samuel Harmatz	Juanita C. Humphrey	Bryan and Meg Keen	Mary Lou and Bill Lange
Harmon Family Trust	Elizabeth Hunter	Gina Keenan-Heepke	Chriscinda and Fabian Lange
Ron Harner	Ryan Huskey	Douglas Kegler	Guy Langevin
The Harnisch Foundation	Judith and Charles Huss	Joell and George Keim	Diane and Jerome Lapham
Harper Collins Publishers	Holly and Thomas Huth	Yvonne Kellar-Guenther	Patti and Thomas Larkins
Jeremiah T. Hart	I Do Foundation	Katrina and Pat Kelley	Pamela and Erik Larson
Brenda Harter	Leonard Iacono	Jed Kelly	Jan and Fred Laughlin
Kristy and Rob Harteveltdt	ICAP Services North America, LLC	Mary Kelly	Laurel Conqueror 451
Harvard University	Independent Bank	Arline and Robert Kennedy	Laurel Conqueror Association, Inc.
Michelle and Hugh Harvey	David B. Ingrey	Sara Kenny	Smoller Scholarship Fund
Peter and Tina Hayward	Sharyl and Roy Inlow	James M. Kerr	Verna and Neil Laurin
Linda Elizabeth Hazen Endowment Fund	Lesley Innes	Dana and Richard Kind	Bonnie Englehardt Lautenberg
Robin and Daniel Hedlund	International Precious Metal Institute New York	Dr. Betty R. King	Joe Lavi
Andrea and Ron Hein Charitable Fund	Clifford W. Ishmael	Kings Drug and Surgical	James E. Lee
Jeff Heitzner	ITG, Inc.	Kings Park Slope, Inc.	Debra Perala and Robert Lemon
Betty and Irwin Helford	Valerie Frost-Atkins and Robert Iverson	Scott Kingsley	Len Camber Grantor Trust
Cathy Duffy and Frank Heller	Larry Jacobson	Shawn Kingsley	Charles and Margaret Levin Family Foundation, Inc.
Robert Helsgott	Linda and Denny Jacobus Family	Michael Kinney	Wendy and Barry Levin
Andrej-Nicolai Henkler	Marc and Karen Jaffe	Margie and Weldon Kirby	Becky and Mark Levin
Lee Henson	Sheryl L. Jedlinski	Rebecca A. Kirk	The Richard L. Levin Family Foundation
James and Marjorie Herald	The Sidney D. Jeffe Trust	Laurie C. Kissell	Lola J. Perniceiaro and Mark A. Levine
Debra Hernberg	Sheila Jefferson	The Kenneth And Laurie Kissell Charitable Foundation	Elayne and Howard Levkowitz
Jim D. Herrgesell	Suzie and Max Jellinek	Leonard Kleiman	Edward and Jami Levy Foundation
Maureen and Michael Hess	Michael A. Jessee	Matt and Susan Klein	Peter Li
David Hidalgo, M.D.	Jewish Communal Fund	Valerie Klein	Jillian Libenson
Peggy and Richard Hieter	Jewish Community Foundation	Barbara and Leonard Kolod	Seth Lieberman
High Five Foundation	Barbara and Mike Johnson	The Donald C. and Norma (Klug-French) Allyn Fund of the Lutheran Community Foundation	Anita and Stanley Liebowitz
The Hill Family Charitable Foundation	Carol Johnson	Gisela Knijnenburg	Fred W. Limbach
Hillard Farber & Co., Inc.	Elaine Joost	Kevin Koch	Karen and Mark Limbird
Susan E. Hillery	The Jordan Company, L.P.	John N. Kogan	Pam Lindroos
Linda and Mike Hinkle	DeNine and Robert Jordan	Marguerite and Morton M. Kondracke	Stuart Liner
Judith E. Tschirgi and Steven J. Hoch	Steven R. Jordan	Norman Konner	Annette P. Lintz
Kay and Grey Hodnett	William H. Josephs	Elizabeth and Ken Kopelman	Paul F. Little
David L. Hoffman	Sheryl Josephson	Paul Korman	The Litwin Foundation
Laurie and Matthew Hogan	Matthew Joy	Mary Beth and Robert Kors	Linda and Robert Livingston
Greg Holden	Dr. Scott Kadlec	Scott Koster	Local 147 Tunnel Workers
	Sharon Kaelin		



2009 Matching Gift Companies

Adele F. Loeb
 Arnold S. Loeb
 Erin Loebner
 Andre Longpre
 Mark Loreno
 Antone and Deborah Lott
 Loyal Order of the Moose
 Karen and Michael Luce
 Michelle Luethy
 Lynn H. Lullo
 Diana Lum
 Evan Lundin
 Michael And Louise Lynch Charitable Foundation, Inc.
 Nancy and Thomas Lynch
 Amy and Brian Maas
 John Mack Carter, Sr.
 Sue and Todd Mackey
 Nancy Macklin
 Madison Avenue Pharmacy
 Melody and Chris Malachowsky
 Charles Malk
 Michael Mandel
 Mike and Sallie Manning
 Marawood Construction Services
 Patricia Marinilli
 Markit North America, Inc.
 Marlette Family Foundation
 Linda Marlowe
 Joanne Marqusee
 Sonya Marsden and
 Elsa Marsden
 Barbara E. Carr and David Marsh
 Heather J. Marsh
 Margaret and Robert Marshall
 Joni and Stephen Martino
 Craig Martone
 Regina and Fred Marvan
 Marcia S. Massee
 Diane and Richard Mason
 Dustin Matthews
 Juanita S. Matthews
 Susan Matthews
 The Philip F. May Charitable Gift Fund
 Robert W. May
 The J. Robb Mayo Charitable Trust
 Nora and Ed McAniff
 James McCarthy
 Docie and Larry McCormick
 Jack McCrory
 Phyllis McDonald
 Thomas McGee
 Jane and Ray McGowan

Abbott Laboratories, Employee Giving Campaign
 Aetna Foundation, Inc., Partners in Community Giving
 Allstate Giving Campaign
 American Express Foundation Company Employee Giving Campaign
 America's Charities, Inc.
 Ameriprise Financial Employee Giving Campaign
 Ameriprise Financial Matching Gift Program
 The Amgen Foundation
 Anheuser Busch, Inc.
 Bank of America Charitable Foundation
 Bank of America United Way Campaign
 The Bank of New York Mellon Community Partnership
 Bank of the West
 Bill & Melinda Gates Foundation
 The Black & Decker Corporation
 Boeing Company Employee's Community Fund
 Bristol-Myers Squibb Company Employee Giving Program
 The Capital Group Companies Charitable Foundation
 Cardinal Health Foundation, Inc.
 Chubb & Son
 Coastal Georgia Combined Federal Campaign
 Davis Selected Advisers, L.P.
 Dell Direct Giving Campaign
 Employees Charity Organization
 Employees Community Fund of the Boeing Company
 Evanston Capital Management, LLC
 The Ford Foundation Matching Gift Program
 GE Foundation
 Give With Liberty
 GlaxoSmithKline
 Global Impact
 Goldman, Sachs & Co. Matching Gift Program
 Google
 Greenlight Capital, Inc.
 Harvard University
 Hewlett-Packard
 Honeywell Hometown Solutions
 IBM Employee Services Center
 Independent Charities Of America
 ITW Foundation
 John Hancock Financial Services, Inc.
 Johnson & Johnson Family of Companies Matching Gifts Program
 JPMorgan Chase
 Keefe, Bruyette & Woods, Inc.
 Kraft Foods Foundation Matching Gifts Program
 KTLA-TV
 Lone Pine Capital, LLC
 Lumina Foundation for Education
 The McGraw-Hill Companies Employee Giving Campaign
 Merck Partnership for Giving
 Merrill Lynch & Co. Foundation, Inc. Matching Gift Program
 Microsoft Corporation Matching Gift Program
 Morgan Stanley
 Mutual of America
 National CineMedia, LLC
 Nestle Foundation
 Pepsi-Cola Company
 Pfizer United Way Campaign
 Portland General Electric Company
 The Prudential Foundation Matching Gift Program
 The Robert Wood Johnson Foundation
 Sabre Holdings United Way Campaign
 Sanofi Aventis Matching Gifts Program
 Takeda Pharmaceuticals Employee Giving Campaign
 Tri-State Health Association Incorporated
 UBS Foundation USA Matching Gift Program
 United Way of Alabama
 United Way of Allegheny County
 United Way of Delaware
 United Way of Greater Twin Cities
 United Way of New York City
 United Way of Somerset County
 United Way of Southeastern Pennsylvania
 United Way of the Bay Area
 United Way of the Columbia-Willamette
 United Way of Tri-State
 Valley of the Sun United Way
 Verizon Foundation
 Washington Mutual Employee Giving Program
 Wellpoint/Unicare Associate Giving Campaign
 Wells Fargo Community Support Campaign
 XL Reinsurance America, Inc.

We are grateful to these companies for their generosity in matching employee gifts to MJFF, resulting in a total match of about \$200,000 in 2009.

\$1,000 or more *(continued from page 31)*

Chris and Linda McKenney
 The McKinney Charitable Trust
 Peter McKown
 Michael B. McMahan
 James J. McNasby
 Mary McNaught
 Joseph M. Meaden
 Medicus Foundation
 Mary Meeker
 Christopher Mellen Family Fund
 John C. Mendillo Family Foundation, Inc.
 Sue and Fred Menowitz
 Rosellen and Barry Mensch
 Charles E. Mensing
 Mary Meola
 Annette Merle-Smith
 Betty and Robert Mero
 Patricia A. Merrill
 Bruce Meyer
 The Meyer Family Fund
 Micanopy Area Chamber of Commerce
 Fran Middleman
 Susan Bartsch and Robert Mileti
 Brian Miller
 Janice Miller
 Steve Miller
 The Miller Family Fund
 Joanne McElligott and Douglas Millett
 Missionfish-Polf
 Phillip Mitteldorf
 Andrea and Michael Mohr
 Shelly and Frederick Molineux
 Phyllis Molyneux
 Sarah Orsay and Russell Montalbano
 Ann B. Moore
 Olga and Thomas Moreland
 David E. Morey
 The Moroze Family Fund
 Dwight and Susan Morrow
 Lou Moskowitz
 Tim and Emily Moulton
 MSR Advisers, Inc.
 John Mullen
 William A. Mundell
 Wendy Munger
 Maureen Ocallaghan-Murphy and John Murphy
 John D. Murphy
 Mark Murphy
 Mary Murphy

Marlene H. Murtonen
 Richard Muscio
 Thomas C. Muse
 Kary and Gary Myers
 NAMS Foundation, Inc.
 National CineMedia, LLC
 National Madison Group, Inc.
 Michael Naumann
 Hedy and Benjamin Nazarian
 Margaret and LeRoy Negus
 Merle and Leonard Nelson
 Richard P. and Faye Nespola Charitable Foundation
 Mary and Alexander Navab
 New England Research and Management, Inc.
 Newark Asphalt Corporation
 Sally Nichols
 Joan C. Niedfeldt
 Anne and Thomas Niesen
 Jeffrey M. Nobel
 Ann and George Norris
 Virginia W. Norris
 Richard Nunnelley
 Kristy and Eric Nuttall
 Ruby and Jack Obenauer
 Edward O'Connell
 Brenda and Budge Offer
 Kit and Roger Olen
 Stephen Olentine
 Madeleine D. O'Mara
 Toni Oosting
 Minna and Duncan Orrell-Jones
 Gerald Ouderkerk
 Robert Ousterhout
 Oxford Industries Foundation
 Patricia and Stephen Paddock
 Timothy Paisley
 Palm Bay International, Inc.
 The Pampered Chef
 Chester Panek
 Paramount Capital Group
 Katharine and Bret Parker
 Clint Parsons
 Pat Boone Foundation, Inc.
 Florence H. Pattee
 Frances Paulsen
 John and Gail Payne Charitable Gift Fund
 Steven and Nancy Payne Fund
 Amy and Brook Payner
 John P. Peavy
 Peerless Clothing International
 Faye Pender

Sandra and Norman Pessin
 Nancy Peterson
 Susan Toeniskoetter and Daniel Petree
 Carrie and William Petty
 PG Productions, LLC
 Rosalind and Edward Pineles
 Pittman Family Foundation
 Pivot Architecture
 The Plymouth Rock Foundation
 Louise Poelzer
 Ann and Peter Pollack
 Pond Jumpers
 Elaine and Henry Pope Jr.
 Carol A. Porter
 Marc Porter
 Poudre Valley Health System Foundation
 Debbie, Rick, Ashley and Jeremy Powell
 Philip Press
 Anthony and Jeanne Pritzker Family Foundation
 Tony Proctor
 Dina and Douglas Propp
 Gail Propp
 Marc Puich
 Mr. and Mrs. Thomas W. Purcell, Jr.
 Teri and Randall Putnam
 Kelli and Allen Questrom
 Sandra and Darrel Quick
 Stephen G. Quill
 R.S. Quality Products, Inc.
 Stewart Rahr
 Lisa and Jim Ramsay
 Karen L. Ramsey
 Kathleen and C. Dean Rasmussen
 Adam Ratica
 Robert Rau
 Raymond Benner Living Trust
 Mary Reaske
 Andrew and Monique Rechtschaffen
 Angie and Steve Redding
 Sharman Reecher
 The Reichert Foundation
 Kurt Reinsberg Philanthropic Fund
 Barbara and Paul Reitzin
 Jack Remnet
 Eileen Rencher
 The RFP Fund, Inc.
 Jill and Scott Rhea
 Dave and Lori Rhodes
 Irene Hegeman Richard, MD

Harry and Verna Richardson
 Joseph Richter
 Norman & Myrna Ricken Charitable Trust
 Barbara and Craig Robbins
 Virginia Robbins
 Susan and Robert Roberts
 Sandy and Mark Robinson
 The Martin and Ellen Robinson Charitable Fund
 Nicholas Roccanova
 Laurie G. Rocha
 Jack Rodin
 Joao Rodrigues
 Margaret and John Roeber
 Larry Rogovein
 Jullie and Garry Rollins Charitable Fund
 Meg and John Rosecky
 Alex Rosello
 Scott Rosenburg
 Eva Yarmo and David Rosenthal
 Mitchell Rosenthal
 Tibby and Abby Ross
 The Rothfeld Family Foundation
 Melissa and Matthew Rubel
 Steven G. Rubenstein
 Terry S. Newman and David B. Rubin Charitable Fund
 Robert N. Rubin
 Ellen Rudman
 Senator Warren Rudman
 The Brenner Rudman Charitable Trust
 Ruppel Lee Family Foundation
 Michelle and John P. Russo
 David Sack
 Leslie Sack
 Stephen Sacks
 Michael E. Sadres
 Sage Software, Inc.
 Elizabeth Doyle and David Saltzman
 Troy and Connie Salyers
 James and Janet Sammer
 Maja Kietzke and Anthony Sanchez
 Dave Sankey
 Jack Savely
 Kenneth Sawka
 Linda Sawyer
 Scars Into Stars Charity
 Joshua Schechter
 Schechter Foundation
 Harry and Lila Schiffman



Suzette and Jay Schochet	Fritz Eric Sperling Jr.	Jean M. Trainor	Westlake Golf and Country Club
Luci Schofield	Lynne and Eric Spillman	Traub-Brittan Family Foundation	John R. Wherry
The Jean and Thomas Schreiber Philanthropic Fund	Justin Spitzer	Terry Tribolet	Grace and Glenn Whitecotten
Nina and Paul Schroder	Don Springer	Tri-State Health Association Incorporated	Mary and Rick Whiting
Schulman Family Foundation	Eric Sprunk	Susanna and John Trittschuh	Whitlock and Associates
Judith and John Schumacher	Simon Stanlake	Linda B. Trugman	Mary E. Whitworth
Marc Schumann	Dan Stark	Todd D. Turnidge	James Wicker
Mark Schupack	Dennis and Janice Steindler	Jane and Wat Tyler	Elisha Wiesel
Mary and Richard Schuster	Drs. Susan and Robert Stephens	Lisa Tyson	Daniel Wilkins
Susan Schutzman	Adam Sticpewich	Unifrutti Of America, Incorporated	Brett, Jack, Charlotte and Cricket Wilkinson
Teresa and Daniel Schwartz	Dana and Andrew D. Stone	United Way of the Columbia-Willamette	Donald E. Will
Meryl and Jeff Schwartz	Jacquie L. Strauss	Nancy and Chris Unrath	Dale Williams
Walter A. Scott	Marie Strebel	Victoria and Walter Van Den Burg	Michelle and Zach Williams
Georgia L. Sebek	Jennifer and Chad Streit	Sally Van Dyke	Lynn Wilmas
Raquel and Andrew Segal	JoAnna Strizic	Loren K. Vanderslik	Allen Wilson
The Selkowitz Family Foundation	Amelie Stroh	Vector Search Group	Murray John Wilson
Ambassador and Mrs. Mel Sembler	Eric Strom	Nicole and Michael Vermut	Pete Wilson
Karen and Samuel Seymour	Harvey and Susan Stromberg	Hope and John Van Beuren	Daniel Wistran
Sara and Mark Shackel	Peggy Sturman	Van Wagner Communications, LLC	Joel S. Wojnilower
Marjory and Jeffrey Sharp	Marianne Sufrin	The Peggy & Ellis Wachs Family Foundation	Meredith Wolff
Clifford A. Sheets	Gary Suttle	The Wagner Family Foundation	Wolters Klumer Health
Marti M. Shell	Georjean Sweis	Valerie Wagner	World-Wide Holdings, Inc. Fund
Pauline and Alex Shender	Anne and Alan Taetle	Wakefern Food Corporation	Robert D. Wortzman
Martin M. Shenkman Revocable Trust	Kathy Taggaes	The Morton & Lillian Waldfoegel Charitable Foundation	Gerald Wright
Marilyn and Rex Sheppard	Karen A. Tamburlin	Suzanne E. Walsh	Jennifer and David Wroan
John H. Ship	Edward Taran Fund	Charlie Wancio	Brooke and Brett Wyard
Debbie and Steven Shough	Lynne Tarnopol	Mary and Jack Ward	Jean Yee
Rose Betty Short	Nancy and James Taylor	William Warden	Wanda and Charles Young
Judith M. Shutz	Nancy and Mark Taylor	Theresa and Bradley Warnecke	Peggy Katz and James Young
The Sidewater Family Foundation, Inc	TCA Bannockburn, LLC	Jason Warner	Mary Ellen and Jim Young
Wendy and Stephen B. Siegel	TD Bank	David And Phyllis Warrick Fund	Fei and Wei Yu
Sierra Microwave Technology, LLC	John Teeger	Phyllis J. Warrick	Larry S. Zajdel
Ben Sihota	TEM-PACE, Inc.	Washington Trust Company	Loreen Zakem
Mr. and Mrs. Steven Silver	Helen L. Temple	Gayle F. Wasserman	Lois and Andrew Zaro
David Sims	A. Thakrar	Wasson Family	Craig Zinserling
Gale Single	Cindy and Robert Theberge	Richard Weber	Daina Zivarts
Jane and Steve Sinton	Lisa Thenell	Wechter Financial Services, Inc.	Denice and Tom Zucca
Aaron Sirulnick	Third Horizon Foundation	Eliot and Beth Wegbreit	
Sanford Sirulnick	Mary and Homer Thomas	Sheila and Edward Weidenfeld	
Bridget Sisson	Michael Thomason	Julie and Peter Weil	
Susan P. Sloan	Michael Thompson	Christine Kelly and Morton O. Weinress	
Paula and Charles Small	Michele and William Thompson	Elaine and Melville Weiser	
Derek Smith	Rose Thorne	Eleanor and Norman Weiss	
Dione and Joseph Smith	Frank and Margaret Throssell Fund	The Roberta and Allan Weissglass Foundation	
Piper and Roger Smith	Tiarks	The Adam J. Weissman Foundation	
Samuel A. Smith	Gail Tomberg	Sharon and James Welty	
Sydell and Ira N. Smith	Mamie Tompkins	Jane Wenner	
Kristin K. Snow	Catherine Toomer	WesBanco	
Jacob Solomon	Jack and Berte Toppell Family Foundation	David Westerman	
Lisa, Jared, Jake, and Mitch Solomon	Bruce Towler		
The Solomon Group	Allison Townsend		
Scott F. Sonkin			

2009 Tributees

*Donations
have generously
been made
in tribute
to the following
individuals and
organizations.*

Ellsworth J. Abare	Robert D. Bruce	Robert G. Deloury	Melvin Gerber	Lo-Ching Hua
Martin Abel	Robert Buchanan	Rocco J. Demilio	Joseph P. Gibbons	Bertha J. Humphrey
Fabrizio Acquaviva	Edward Burke	Lorraine DePompa	Jan Gibson	Arthur L. Humphrey
Margaret E. Allen	William O. Burnett	David F. DeWaters	Joseph W. Gibson	John R. Humphrey
Martha L. Allen	Jerry R. Burns	Marina J. Dewey	Jack Giesecke	William H. Hyde
Sara G. Allen	Barbara C. Calvert	John A. Dieken	Bob Ginsberg	Frances V. Ireland
Dave Alpert	Janice Campbell	Manuel V. Diez	Albert B. Glickman	Dave Iverson
Mark L. Amoss	Minnie Cantor	Rudolph DiNunzio	David Glickman	Philip R. Jamison
Eleanor H. Ancona	Ross M. Canty	Mary C. Docherty	Judith Glickman	Joseph S. Jankovic, MD
Samuel M. Anderson	George W. Carpenter	Charles Doering	Sandra Gluck	Alberto Jimenez
Jerald L. Andrew	Robert M. Carriger	Alex Doolas	Esther Goldberg	Charles L. Johnson
Paula P. Archinaco	Patrick A. Caruso	Roger Durban	Sheldon Goldstein	Gerald L. Johnson
Joseph P. Armao	Barbara Carver	William Dusterhout	Margot Gosen	Rhona B. Johnson
John E. Arnet	Margaret W. Caullwine	Thomas D. Ebner	David A. Graffam	Freeman P. Jordan
Ian Arons	Elizabeth V. Cavano	Lois A. Elander	Lafayette M. Gravely	Julia Jordan
Tim Ashe	Vincent Celenza	Anne-Cecilie Engell Speyer	Rhonda L. Greear	Mary Kamal
Louis W. Astorino	David Cerrina	Thomas English	Dorothy Greene	Delphine Kaminski
Mary Athanas	Josephine Cerrina	Morris L. Estess	Elliott S. Greenspan	Amalia S. Kaminsky
Robert Audette	Joyce Chalnack	Everyone at Rock Steady Boxing	Matthew Greenstein	John E. Kandel
J B	Chinghwa P. Chang	Everyone with Parkinson's Disease	Curtis L. Greenway	Larry E. Kandel
Marian L. Badendieck	Elizabeth A. Chase	Dorothy Evslin	Rosa L. Griffin	Marshall A. Kaplan
William H. Bagot	Arthur A. Checchi	Anne Eyes	Grace S. Griffith	Maurice Kaufman
Woodrow H. Baker	Wes Christie	Ralph P. Fader	Carl Grossman	Ernest Kellar
Paul Balerud	Ronald T. Chung	Jack Famularo	Fred W. Grotophorst	S. Arliss Kemp
Shirley Bandy	Jeanne A. Clare	Jeanne H. Faulkner	William A. Gruy	Violet M. Kent
Bettye Baria	Patricia Clarke	Natalie H. Fay	Paul Gustavson	Clifford R. Kesler
Gerald Basie	John W. Coffey	Albert L. Fierro	Cindy Hadaway	John W. King
Frank M. Bass	Barry J. Cohen	Karen L. Finerman	John S. Hager	James C. Kirk
Arlene M. Bauer	Louis Cohen	Emanuel Finkelstein	Sylvia Harman	Mary L. Kissel
Richard Beck	Richard Cohen	Patrick Finnegan	Ramona A. Harmon	Mary L. Kissell
Shirley R. Belch	Howard Cohan	Richard H. Fitzgerald	Kermit Harner	Eugenia Koog
Thomas H. Belt	Gerald F. Conlin	Ronald H. Fitzsimmons	Stanley Hart	Frank Kotch
Raymond Benner	Joseph E. Connor	Earle R. Flesher	William J. Harte	Edward W. Kowalczyk
Jerry Bernstein	William Conroy	John L. Flowers	William Hauf	Selma I. Koznek
Judy Bernstein	John B. Cooke	John J. Foley	Susan B. Haverstock	Barbara Kraly
Shirley C. Berryessa	Hiram L. Cooley	Manuel Forman	Leo E. Helander	Clyde L. Krogh
Howard Bidwell	Denise Costa	Julian F. Forthofer	Jerome Helgren	Robert Kroupa
Lois Binder	Lucien J. Cote	Lawrence E. Forthofer	Anita S. Henry	Renee Kumetz
Janet Blazon	Robert Cowhey	Michael J. Fox	Patrick Henry	Gerald T. Kurtz
Gary R. Bloom	Don Crisup	Charles Frantz	Dena Herema	Bonnie Kutas
Eugene J. Boros	William C. Curtis	Theodore Frazis	Michelle Hespeler	Dirk A. Kuyk
Michael Bosse	Linwood Custalow	Helen Fronstin	Patricia C. Hester	John N. Lam
Freida Boujoukos	Dad	Daniel B. Frost	Leonard F. Hill	Bernard C. Lamas
Sharon Boyd	Antoinette R. Dalo	Cynthia Fucci	Naomi Hoffman	Michelle D. Lane
Francis B. Bracken	Joseph A. D'Anna	Richard Garber	Robert B. Holland	Selma Lanes
Jack Breed	Rex Davis	Joseph A. Garraffa	Jim Holt	Robert E. Larson
Susan B. Bressman, MD	Susan M. Davis	Natalie Gasior	Katie Hood	Elliott Latez
Lisa Brodsky	Glenn Davis-Anacker	Abraham Gaslow	Richard E. Hoover	Robert F. Latimer
Robert M. Brody	James N. De Haaff	Paula Gaston	Sarah K. Horn	John J. Laureto
Marie Brooks	Victoria Dean	Patricia Gateff	Warren Hottenstein	Neil Laurin
Janet L. Brown	Donald H. DeHayes		Doris J. Houser	David M. Laushey



Stephen Lawrence	John J. McNamara	James J. Peters	Jerome A. Sertick	Colburn R. Thomason
Megan Layer	James W. McTague	Jim Peterson	Robert W. Shackleton	Andrew Tobias
Sylvia M. Lazar	Robert G. Meelheim	Richard T. Peterson	Paul R. Shalita	Jack Toppell
Wanda M. Leach	Richard L. Meirink	Homer E. Pfefferkorn	Ruby Shepherd	William Torresi
Merle Leake	Mike Meltzer	Raymond E. Pittman	Jerome P. Shifter	Judith A. Towler
Joy Leichenger	John C. Mendillo	Albert B. Polen	Yaeko Shintani	Jennifer Trittschuh-Valles
Roland H. Leisy	Barry Mensch	Stephen M. Pollan	Joanne Ship	John R. Twiss
William B. Leonard	Lavonne S. Mensing	Joel Portnoy	Debbie Shough	Miller H. Ullmann
George Lerman	Scott Meril	Jack M. Posen	Georgina Silva	Martin B. Unger
Martin Levin	Cora Messinger	Lane D. Powell	Evelyn Simon	Alvin Vanderslik
H. Burton LeVine	Joyce A. Metcalf	Joel Press	Melvin Simon	James Vaugh
Gustave L. Levinson	John R. Meyer	Dolores M. Princiotta	Alexander M. Sinclair	Virginia Norris's Mother
Arnold Levy	Patricia Michaels	Robert Pritzker	Merle E. Singer	Thomas A. Wagner
Edwin A. Levy	David O. Miller	Charles H. Pulley	Frederick J. Sisson	Irene Wakabayashi-Yanaga
Linda Avey's Father	Leo Miller	Sue B. Pye	Mary E. Skewes	Sharon Walker
Ariel Linden	Shirley Miller	Thomas B. Ramsey	Charles Sklar	Anthony W. Walsh
Arthur E. Lindroos	Jewell O. Mohn	Gary L. Randall	Leo J. Sklar	Antoinette Warden
David F. Lindsley	Jerry Moore	Richard Randall	Patricia A. Sloan	Stephen D. Weinress
Gerhard D. Linz	Monica Morekin-Serfas	Theodore M. Ratica	Edward Smallwood	Leona Welty
Jennifer Lipschultz	Thomas P. Morrissey	Kenneth A. Reecher	Clare D. Smith	Stephen Welty
Marc S. Lipschultz	Mary C. Murphy	Kevin Reilly	Guy H. Smith	Annette Westerman
Val Livingston	Thomas P. Murphy	Margaret M. Rhea	Hugh P. Smith	Bill J. Whitworth
Barbara Lizerbram	Wilma M. Murrin	Roger J. Rice	Ira N. Smith	Richard J. Wiederhorn
Richard Locke	Donald J. Murtonen	Jacqueline Richard	Princie L. Smith	Earl Wiener
Jim Long	Cheriyath Nath	Deborah Ridel	Sandra M. Smith	Jack Wilco
Delores Loreno	Noel Nathanson	Antonio Rimanelli	Martha Snow	Samuel A. Wilkinson
Donald N. Lykens	Susan Nathanson	Robert E. Roderick	Mary L. Solema	David R. Williams
John T. Lykouratzos	Maurice R. Nazareth	Sonya Rodin	Judith C. Spencer	Linda Williams
Fred Mann	Robert G. Neale	Jean Rooney	Emily Spiegel	John S. Wilson
Michael J. Manning	Ron Nelson	Richard M. Rothenberg	Jerry Spiegel	Elsie Winn
Elena Manno	Joseph D. O'Brien	George W. Rourke	Ann K. Spier	William H. Winston
Ellis L. Marks	Catherine S. O'Connell	Judith F. Rubin	Jack Spillman	Mildred Wise
Ralph H. Marquet	Mary L. Ostrowski	Josef Ruepp	Warren E. Sprague	Sue Wojnilower
Robert Marvan	LaVonne Pagelow	Helen Runnels	David Steen	Marty Wolff
Harry Maunu	Donald G. Paige	Alfred G. Russell	Ray Steinman	Dorothy M. Yares
Marilyn H. Mayer	Mary A. Palmer	Kenneth B. Russell	Susan A. Stephens	Barbara P. Young
Teddy Mayer	Muriel J. Parmenter	Hans Salomon	Donald J. Stewart	Charles W. Young
Mitsuko McCandlish	John Paron	Harry Salter	Harry J. Stingley	Miriam Zaretsky
Ida L. McClure	Hillery A. Parrack	Jessie Santini	Stanko S. Stojkovic	Marta Zivarts
Sean McConnell	Robert W. Patin	Edith Saunders	Howard M. Strauss	Iva V. Zucca
Cleo McCroden	Narhari Patolia	Shiv L. Sawhney	Mary G. Strazz	Seymour Zwerin
Rosemarie McCrory	Joseph C. Pattee	Giuseppe Scattone	Edward A. Strebel	
Kathy McCune	James H. Patterson	Helmut M. Schaffler	Robert F. Streit	
Thomas J. McDade	Anne Paykos	Carolyn Schenker	Joseph J. Strizic	
E. Janet McDonald	David H. Peery	Gail Schmerl	Shirley Stroud	
Edward McGah	Claiborne Pell	Richard L. Schneider	Eva Stuenkel	
Mary Etta McGaughey	Harold D. Pendergraft	Thomas M. Schroeder	Arnold L. Sutta	
Patrick T. McGowan	Robert E. Penny	Margaret M. Schuman	Craig Swanson	
Carol R. McGuire	Ruth Perrigino	Elaine W. Schuster	Paul Swanson	
Louise McLaren	Mary B. Perry	Frank G. Sebek	Robert O. Sykes	
James D. McMahon	Norman H. Pessin	Delores A. Seeber	Robert Temple	

TEAMFOX

In 2009, over 1,000 dedicated Team Fox members collectively raised nearly \$3 million to support The Michael J. Fox Foundation's high-impact research programs. Whether they flip pancakes, start a golf tournament, hold a yard sale or run a marathon, these passionate and creative people all over the world form an unstoppable team that keeps finding more ways to help advance the Foundation's vital work — bringing us all closer to new treatments and a cure for Parkinson's disease.

\$50,000 or more

Susan Bilotta
Tips for Parkinson's

Michael Costa
The War on Parkinson's Softball Game

Susan Kauffman
Kickin' Parkinson's One Lap at a Time

Mary Anne Ostrenga
Garden Walk & Sunset Reception

JoAnn Runk
"Music for Parkinson's" Benefit Concert

Wilkins Media Company
Polo for Parkinson's

The Woods Family
The New England Parkinson's Ride

\$25,000 or more

Delaware Pancakes Committee
1st Annual DE Pancakes for Parkinson's

David Eger
7th Annual Music for Parkinson's Research Concert

The Greif Family
5th Annual Friends of Parkinson's Twilight Golf Outing

Larry Howald
Seven-In-Seven

Josephine Poehlmann
7th Annual Benefit in Memory of Tom Poehlmann

Rucker's Candy
LCPDA Golf Classic Fundraiser

\$10,000 or more

Arrowhead Inn
Arrowhead Open Golf Classic

Skip Bailey
Coast to Coast for Parkinson's Research

Marian C. Bell Foundation
P.A.R. for Parkinson's Golf Event

Tim Blair
Antarctica Marathon

Peter Bleiberg
Boston Marathon

Rosemary Beach Foundation, Inc.
The Jim DelMauro Rosemary Beach Run

David Dorsey
Hilton Inn at Penn Reception and Auction

Catherine Dumoff
Rally for Parkinson's Tennis Tournament

Eagle Bridge Foundation
Sigma Chi EBF Golf Weekend

Tracey Earl
Buckles and Spurs Gala

The Epstein Family
Epstein Family Pancakes for Parkinson's

Michael Feinsod
City to the Sand 100 Mile Ride

Nicholas Frasso
Help Hook The Cure Striped Bass Derby

Gene Gaunt
Boston Marathon

Doug Gigliotti
Steak Fry

Jayne Godfrey
The Bluegill Benefit

Yonina Gomberg
NYC Half Marathon

Team Gordon
Providence Rhode Races

Junior Hollywood Radio and Television Society
JHRTS Holiday Party

Eugenia Koog
Play to Find a Cure for Parkinson's Disease

Neil Korf
Team Fox Fundraiser

Pinky's Passion for a Parkinson's Cure
Pinky's Passion for Fashion

Zachary Rau
Dic-Wisco Farms Pars for Parkinson's Golf Outing

Ryan Reynolds
Team Fox Celebrity Chair

Mara Richards
Peaks for Parkinson's

Gary Schmitz
Walkfest '09

Kyle Shackleton and Drew Shackleton
Chicago Marathon

Sean Slaughter
Team Fox Tennis Tournament

Michael Spanier
Chicago Marathon

Team N2Tri
Longhorn Ironman 70.3

University of Virginia
5th Annual Pancakes for Parkinson's

The Wistran Family
3rd Annual North Shore Walk for Parkinson's Disease

Elizabeth Woodbury
Annual Spring & Summer Style Show

\$5,000 or more

Andrew Allen
Spin for a Cure

Laurie Allen
Reach Out Hearts

Alpha Tau Omega
3rd Annual Charity Chili Cook-Off

John Antonini
Austin Triathlon

Jan Bogner
Put the Fire Out for Parkinson's

Brendan Callahan
Boston Marathon

John Carter
Racing the Planet: The Gobi March

Jennifer Chadwick
Tiptoe through Tulips

Alyssa Johnson and Barry Cohen
Wet Dogs Calendar / NYC and Boston Marathons

Carol Constable
Golf for Parkinson's Benefit

Jody Culmone
Team Fox Fundraiser

Dance for a Cure
Ciao Parkinson's

The Deery Family
Dick Deery Run/Walk for MSA

David Diedffenbach
Boston Marathon

Sean Ferrell
Marine Corps Marathon

Meg Fisher
1st Annual Pig Roast for Parkinson's Research

Timothy Fitzgibbons
Boston Marathon

Debby and Lou Flancbaum
Pars for Parkinson's

Ryan Grant
Pints for Parkinson's Disease Fundraiser

Oliver Holler
To The Future: Transcontinental Mission

Kasey Jaffe
Party and Silent Auction

Lori Jawitz
Unity Walk

Warsaw Center
Jog for Jim

Catherine Keane
Boston Marathon

Brad Kear and Lois Kear
Party for Parkinson's

Diane Kinsey
Walk With Mary

Steve Klassen
Fundraising Letter Campaign

Tavia Kowalchuk
Baltimore Half Marathon

Al and Beth Levine
Hockey and Triathlon Events

Jon Maier
Mighty Hamptons Triathlon

Gary Marks
Patriot Golf Tournament

Erin Raitt and Scott Martineau
ESi Ironman 70.3 Augusta

Steve Miller
Boston Marathon

Eric Neiman
Seussical at Tri-Valley Rep Theatre

Ohio State University
2nd Annual Pancakes for Parkinson's

Gail Oliver
Mrs. Mo Memorial Golf Tournament

Stephanie Paddock
NYC Triathlon

Michala and Dennis Witas
Pubbin' for Parkinson's

Sarah Rasmussen
Team Fox Golf Tournament

Ken Reichel
50 Marathons Before 50

Josh Rozbruch
Boston Marathon

Richard Sanks
Ironman Germany

Amiel Sawdaye
The New England Parkinson's Ride

Kathi Sawka
Boston Marathon

Team Meem
Utica Boilermaker

David Teitelbaum
Knight-Teitelbaum Wedding

ING NYC Marathon

Team Fox's growing marathon program was honored to be included again as an official charity partner in the 2009 ING NYC Marathon. 220 runners from four countries and 21 U.S. states put one foot in front of the other for 26.2 miles to raise over \$857,000 for The Michael J. Fox Foundation's research toward a cure.

Sarah Washerstein
1st Annual Dance Party For Parkinson's

Gretchen Weber
Ironman

Eileen Werndorfer
Brookfield Parkinson Run/Walk

Tim Wheeler
Cole & Friends: An Elegant Evening

Kathy Zweifel
Party for Parkinson's

\$2,500 or more

Steve Alten
Team Fox Fundraiser

Cintra Bentley
Chicago Marathon

Benjamin Bernstein
NYC Half Marathon

Bryan Blackorby
ING Atlanta Half Marathon

Philip Bloom
Black Bear Triathlon

Michael Bologna
Chicago Marathon

Beth Buzza
Scott Tinley's Adventures Road Triathlon

The Campanelli Family
Campanelli's Walk for Parkinson's

Greg Carollo
Chicago Marathon

Lisa Clark
Boston Marathon

Janet Clough
Team Fox 5 Mile Walk

David D'Arcy
North Shore Century Bike Ride

Lisa de Lusignan
Conchman Triathlon

Larry Frank
37th Annual California 10

Jamie Franz
Chicago Marathon

Laura Gryniewicz and Lorraine Gryniewicz
Under Armour Baltimore Running Festival

Deborah Hagel
Team Fox Dinner Party

Hal Halvorsen
Boston Marathon

\$50,000 or more

Amar Kuchinad

\$25,000 or more

Michael Dubin
Veronique Enos
Tim Reid

\$10,000 or more

Yves Chabot
Gregory Conen
Dan Meador
Nike, Inc.
Kenneth Olson
Kevin and Colleen Schirf

\$5,000 or more

Anne Elizabeth Baker
Alex Bird
Gary Cervantes
Steve Denker
Jeremiah Driansky
Kris Dworkoski
Patrick Egan
Lauren Estabrook
Ahmed Fahim
Kurt Fielder
Terence Flannigan
Ronald Garriques
Shannon Goff
Randy Greben
Andy Hunt
Christine Kevan
Ken Kubota
Gayle Proctor
Barbara Etzel and Rob Basch
Erin Robbins
David Sack
Lorri and Terry Scovill
Nina Tringali
Sally Washburn
Stephanie Wenning and Lauren Wenning
Matt Wilbur
Donna Williams

\$2,500 or more

Liza Abad
Fahad Ahmed
Heather Allerdice-Gerow
Nora Ammar

Jen Anderson
Adrienne Baranowicz
Alex Beck
Rebecca Bennett
Eric Bland
Clayre Brown
Jennifer Browne
Tony Carbone
Vincent Carrozzolo
Andrea Castillo
James Chmiel
Doreen Clifford
William Connelly
Rebecca Corso
Blair Coulson
Dana Coyle
Tim Crowley
Dayna De Simone
Kimberly Dewalt
Simon Esposito
Scott Fahey
McKee Falk
John Fitzmaurice
Robin Flanz
Chris Grannan
Sarah Hansen
Trisha Hanson
Caitlin Harrington
Bethany Hoffman
Rusty Holzer
Lori Hongach
Anders Hyde
Roger Imhof
Richard Jones
Jonathan Kaida
Kari Keane
Michael Kelly
Jennie Kelly
Julie King
Shawn Kingsley
Scott Kingsley
Nathan Kirk
Jesse Kraus
Rachel Kreisman
Jon Kully
Michele Kustera
Shawn Leo
David Levine
Jeremy Levy
James Lin
Erin Loebner

Noah Lucas
Michael Lyons
Naz Majidi
Jason Mang
Laura Manofsky
Joseph McDonnell
Pamela McIlvaine
Andrew McLean
Mike McPartland
Deborah Meyer
Kristine Miller
Gwen Miller
Brian Monk
Annick Mullen
Kristin Murray
Keith Nelson
Mariel O'Brien
Daniel O'Reilly
Lauren Ostendorf
Caitlin Peters
Gail Peters
Gina Pham
Rebecca Philips
Nancy Polstein
Pat Price
Andy Renton
Siobhan Roberts
Joao Rodrigues
Paul Roer
Maren Rosen
Susie Rosenthal
JP Rutigliano
Susan Ryan
Lauren Rybas
Emily Sarokhan
Karin Sawyer
Rob Scheifley
Gwen Schroeder
Karen Segall
Jennifer Senske
Jennifer Shea
Nicole Siefert-Fink
Corrin Silver
Phil Sosnow
Stephen Stowe
Frank Stramiello
Jacquelyn Strycker
Michael Sunwoo
Jennifer Szpila
John and Susie Teal
The Sauder School of

Business
Amberleigh Thetford
Lucy Evans Ulmer
David Weber
Abby White
Margaret Whiting
Peter Wilson
Murray John Wilson
Ronald Wong
Aileen Wong
Jean Yee
Patti Yoon
John Zainea

\$1,000 or more

Danielle Andreasi
Daryl Austin
Jason Bennett
The Coffee Bean & Tea Leaf
Jennifer D'Aoust
Jamin Davies
Joey Davis
Steve Day
Timothy Diamond
Thomas Donahue
Phil Evans
Bruce Fina
Daniel Gercke
Andrew Gordon
Wendy Grider
Jeremy Heckerling
Karen Janos
Christine Leslie
Alissa Lifshitz
Matthew MacGregor
Leslie McBeth
Katherine McDonald
Brian McManus
Patty O'Connell
Kevin O'Connor
Joanna Pedersen
Jason Roer
Daniela Rosello
Alex Rosello
Erin Sheard
Neil Thomson
David Wilburn

TEAMFOX

(continued from page 37)

Patrick Hatton
Chicago Marathon

Lori Hes
More Marathon

Jeffrey Joseph
Fireworks for Fox

Natalie Karp
Canyon Ranch Group Trips

Mount Allison University
Pancakes for Parkinson's

Jillian Libenson
1st Annual Nona Libenson 5K/10K

Linda Lyle
Pay Forward for Parkinson's

Chaya Mallavaram
Memorial Gifts

Jason Matter
Triple Bypass Bike Ride

Jill Matter
Triple Bypass Bike Ride

Dustin Matthews
Hacker's Cup Golf Tournament

Robin Maxcy
Boston Marathon

Clent Mericle
Hit the Road Jack 5K Run/Walk

Amy Miller
Twin Cities Marathon

The Monusky Family
*2009 "60 for 60" Campaign for
Parkinson's Disease Research*

Kevin Moss
South Florida Team Fox Scuba Dive

Rosemary Pepe
Party to End Parkinson's

Jennifer Porter
Popcorn for Parkinson's

Colette Porcelli Lettieri
Inn at Quogue Fashion Show

Kim Ready
Cowtown Ultra Marathon

Samuel Ross
Marine Corps Marathon

Running for Papa
Nashville Country Music Marathon

Lori Saviers
*10 Mountains 10 Years:
A Quest for the Cure*

Trey Sebus
Chicago Marathon

Steve Spencer
*"You Can't Take It With You"
Play Proceeds*

Brian Thorne
*2nd Annual Friends of
Team Fox Holiday Party*

Kari Travis
Boston Marathon

Colleen Wuebben
Wuebben Family Skate-a-Thon

\$1,000 or more

Maureen Ashdown
Pocket Change 4 Parkinson's

Berkeley County Parkinson's
Support Group
Bonanza and Softball Tournament

Richard Broughton
*The Annual OBX CruZ for the Cure of
Parkinson's Disease*

Jessica Brown
Capital of Texas Triathlon

Sarah Bunn
"Detoxify Your Life" Seminar

Lou Bushinsky
Chicago Marathon

Grainne Byrne
NYC Half Marathon

Bonnie Cha
NYC Half Marathon

Vicky Clark
Sale for a Cure

Ken Clary
WhistleStop Marathon

Jennifer Cogan
Philadelphia Marathon

Eileen Colon
The Army of Change

Katie Congdon
Willow Tree Half Marathon

John Cuccinello
Jarden Westchester Triathlon

Laura Dalle Paze
Warrior Dash

Stella Darby
Liversedge Half Marathon

Jeffrey Davis
Team Fox Athlete

Michelle De Luca
NYC Half Marathon

Robert Denlow
Boston Marathon

Meghann Dials
Illinois Marathon

The Dobrez Family
Team Fox Fundraiser

Greg Drumheller
*The Jerry G. Barnhart
Memorial Poker Tournament*

Martin Eldred
Humpy's Classic Marathon

Elaine Ellis
Premier Jewelry Show

Inci Ertan
Dinner & Cooking Class

Ian Fagan
NYC Half Marathon

Brandy Fain Netzer
ING Half Marathon

Dani Farber
NYC Half Marathon

Miranda Feldmann
Silly Spooky Movie Nights

Christine Finan
NYC Half Marathon

Morgan Fixel
Team Fox Fundraiser

Hailey Flynn and Robin Lee
NYC Half Marathon

Linda Foresha
Pirouettes for Parkinson's

Sheldon Garfinkle
NYC Half Marathon

Helen Gerry
Purse Sales

Alan Gettis
Philadelphia Marathon

Mark Gherty
American Birkebeiner

Jacqueline Gibbons
Hartford Half Marathon

Jill Goldenziel
Boston Half Marathon

Eugene Gurfkoff
Team Fox Fundraiser

Sandra Haas
NYC Half Marathon

Diana Hadden
*Cincinnati Flying
Pig Marathon*

The Hanna Family
Hanna Family Legacy

Gerard Hayes
NYC Half Marathon

Adam Hegge
Pull for Parkinson's

Chad Henson
*Dallas White Rock
Marathon*

Kieran Hughes
Special Occasion Gifts

Larry Ice
*Parkinson's Awareness
Building Events*

Lenore Imhof
*Jarden Westchester
Triathlon*

Jordan Isenstadt
NYC Half Marathon

Karen Janos
Team Fox Fundraiser

Lisa Jay
*Spectrum- Fall Dance
Concert at Laguna
Beach High School*

Jennifer Johns
Boston Marathon

Tara Jay Johnson
*The Richard L. Johnson
Memorial Golf Tournament*

Brad Kear
Multiple Marathons

Mary Kelly
Team Fox Athlete

James Knuckles
Chicago Marathon

Jeffrey LaGrange
*Board of Education
Dress Down Day*

Tracy Lehnecker
*Medicus Foundation
Fundraising*

Brian Levy
NYC Half Marathon

Michael Lewis
Honor Gifts

Peter Liberto
Friends Helping Friends

Jennifer Love
Pancakes for Parkinson's

Nate Lukas
*More than Words:
A Benefit Concert*

Madison Lyleroehr
*Vocal Performances
and CD Proceeds*

Edward Macdonald and
Nikita Romanoff
NYC Half Marathon

Chris Magoon and
Katie Magoon
Providence Rhode Race

Lisa and Branko Maric
Joint Birthday Party

Theresa Marran
Team Fox Dessert Buffet

Mark Mason
Kona Ironman

Cassandra Mastrianni
*Pizza for Parkinson's and
Day of Enchantment*

Soania Mathur
Team Fox Fundraiser

Sean McDonald
*Cedar Springs Circle Annual
Crawfish Boil*

Sasha Mobley
Healdsburg Half Marathon

Amanda Neal
Tour of Anchorage



Mary Ann Neilson
*2nd Annual Keystone State
Corvette Club Poker Run*

Mike O'Brien and Tom O'Brien
Ironman St. George

Patti Olszewski
*Chicago Rock 'n' Roll
Half Marathon*

Miranda Owens
Phoenix Rock 'n' Roll Marathon

Gaetano Parrinello
NYC Half Marathon

Jeanette Pena
*Chicago Rock 'n' Roll
Half Marathon*

Chris Piper
*Chris Piper's Grand Loop
Mountain Biking Adventure*

Allison Platt
Party for Parkinson's

Larissa Raze
Team Fox Fundraiser

Michael Redfern
Multiple events

Jeannette Reiff
Pedal for Parkinson's

Mary Rich
Team Fox Wristbands

Staci Roberts
Team Fox Athlete

Beth Salyers
*Napa to Sonoma Wine
Country Half-Marathon*

Lenni Sand
Team Fox Fundraiser

Reggie Scarpa
Hartford Half Marathon

Nikki Schiro
NYC Half Marathon

Molly Scott
Molly's Mission for Grandpa

Kara Sessums
NYC Half Marathon

Enzo Simone
The Army of Change

Brad Smith
NYC Half Marathon

April Soggi
NYC Half Marathon

Lee Sommers
Team Fox Fundraiser

Rik Spier
Mini Marathon 5K Walk/Run

Arun Subramanian
*Walk for Research to
Fight Parkinson's*

Jacqueline Talarico
Jewelry Sales

Mark and Mary Sue Taylor
Kroger cards distribution

Thomas Tedesco
Team Fox Athlete

Emily Twiss
Austin Half Marathon

Andrew Vale
Marine Corps Marathon

Garth Wakeford
NYC Half Marathon

Jason Warner
*Gordon Ferguson Yackle's 10K Run
Against Parkinson's*

Renee Wegrzyn
NYC Half Marathon

Meg Weidner
Cupcake Mission

Diana Wiesner
Capital City Half Marathon

Brianne Yantz
NYC Half Marathon

Jonah Yesowitz
Kid's Carnival of Caring

Damon Zaleski
Chicago Marathon

2009 Community Fundrasiers

The Foundation is grateful to the following donors for their generous efforts to raise funds and awareness for MJFF and Parkinson's research through community fundraising events.

\$25,000 or more

23andMe
Michael Cotoia

\$10,000 or more

ITSource Technology
Sydney Goldstein

\$5,000 or more

ALL TRI, Inc.
CSRA PD Support Group Walkathon
Preston L. Lowe
Parkinson's Support Group of
Rochester NY, Inc.
Debbie Shough
Summit County Parkinson's Support Group

\$2,500 or more

Robert Benjamin/Light of Day Foundation
California Jurisdictional Convention
Illinois Shotokan Booster Club
JTB International Ltd.
Megan Layer
Rocking For Parkinson's Disease
Research Foundation, Inc.
Brad Schenker Bar Mitzvah
Sandy Smith

\$1,000 or more

Aeroquip Credit Union
Judith Binder
Karen deGraaf
Stephen E. Farris
Federal Aviation Administration
Mark Friedman
Ariel Linden
Hamden High School Hockey
Alumni Association
I Do Foundation
Micanopy Area Chamber of Commerce
MissionFish
Eileen O'Neill
Scars Into Stars Charity
Anne-Cecilie Engell Speyer and Rob Speyer
Tokio Marine Management, Inc.
Wells Fargo Community Support Campaign
Westlake Golf and Country Club

*We have made
a concerted
effort to
accurately
list all donors
of significant
contributions
in 2009.*

*If your name is
misspelled or
missing from
this report,
please accept
our apology and
email the correct
information to
donations@
michaelfox.org.*


6 MJFF's place on Worth.com's 2009 Elite List of the 10 most fiscally responsible charities

2009 Financial Highlights

The Michael J. Fox Foundation believes donors have a right to look for measurable returns on their investment. We operate according to best practices and remain accountable to our donors and the Parkinson's community for ensuring maximum effectiveness. Our leadership was recruited from the worlds of finance, management and neuroscience, bringing strategic skills, scientific and operational expertise, and an investment professional's sensibility to the management of the Foundation.

- We constantly monitor costs to maximize the value of donations. Since inception, 86 cents of every dollar we've spent has gone straight to our research programs effort.
- We are outcomes-focused, tying grant payments to the achievement of specific milestones, troubleshooting challenges if

MJFF Efficiency 2000–2009



“Donors to The Michael J. Fox Foundation for Parkinson’s Research have provided funds used to expedite grant processes, establish benchmarks for progress, apply continuous evaluation practices, and invest in a portfolio of promising research initiatives simultaneously... helping to reduce the overall risk of research investments, create new incentives for scientists and change the culture and expectations around medical research.”

*Issue Brief: Investing in Medical Research,
Arabella Philanthropic Investment Advisors (2010)*


they arise, and halting funding if the science stalls. And we demand the same accountability and transparency of ourselves as we do of our awardees.

■ We deliberately have no endowment, because we believe that to speed a cure for Parkinson’s disease, our capital needs to get into scientists’ hands as quickly as possible — not sit in an endowment or reserve.


MJFF ended 2009 closing in on the \$200-million mark in research funded since inception. Ultimately, though, we measure our impact not in terms of dollars spent, but in terms of scientific solutions that produce tangible improvements in patients’ lives.

2009 financial highlights follow. Full audited financials and our most recent IRS Form 990s are available at michaeljfox.org.

Research Allocation 2009



Growing Investments in PD Research 2001-2009



Dollar amounts in millions. Does not include 2001 R21 awards in partnership with NIH.

The Michael J. Fox Foundation for Parkinson's Research

Consolidated Statements of Financial Position

As of December 31,	2009	2008
Assets		
Cash, cash equivalents and investments	\$ 33,422,684	\$ 30,962,536
Contributions receivable, net	35,401,415	26,762,424
Prepaid expenses and other current assets	156,687	162,958
Security deposits	33,061	33,061
Inventory	28,036	
Property and equipment, net	278,893	388,610
Total assets	\$ 69,320,776	\$ 58,309,589
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 1,713,780	\$ 1,066,594
Grants payable, net	42,161,174	38,882,706
Loan payable	1,000,196	1,000,196
Interest payable	59,511	13,089
Deferred rent	358,114	367,192
Total liabilities	45,292,775	41,329,777
Net Assets:		
Unrestricted	2,345,986	(5,516,236)
Temporarily restricted	21,682,015	22,496,048
Total net assets	24,028,001	16,979,812
Total liabilities and net assets	\$ 69,320,776	\$ 53,309,589

Note: Investments are highly liquid.

The Michael J. Fox Foundation for Parkinson's Research

Consolidated Statements of Activities

Year Ended December 31,	2009	2008
Public support and revenue:		
Contributions	\$ 45,433,897	\$ 35,335,877
Special events	5,825,680	6,741,990
Investment income	119,440	662,655
Miscellaneous income	37,425	25,682
Total public support and revenue	51,416,442	42,766,204
Expenses:		
Program services	39,153,137	36,236,785
Management and general	1,263,737	1,093,996
Fund-raising	3,951,379	4,130,806
Total expenses	44,368,253	41,461,587
Change in net assets	7,048,189	1,304,617
Net assets, beginning of year	16,979,812	15,675,195
Net assets, end of year	\$ 24,028,001	\$ 16,979,812

Todd Sherer (left), vice president, Research Programs, MJFF, and Andrew Singleton of the National Institute of Aging (NIH) and MJFF's Executive Scientific Advisory Board at the Investigators' Meeting for the Parkinson's Progression Markers Initiative (PPMI) study launching in 2010.



Progress:

The 2009 Annual Report of The Michael J. Fox Foundation for Parkinson's Research was published in June 2010. It is available in PDF format at www.michaelfox.org.

Katie Hood
CEO

Michael J. Fox
Founder

Deborah W. Brooks
Co-Founder

Editor:
Holly Barkhymer
*Associate Director,
Communications*

Writers:
Holly Barkhymer
Katrina Kahl
*Associate Director,
Communications*

Designer:
Susan Shaw

The Michael J. Fox Foundation is a 501(c)3 nonprofit organization.

© 2010 The Michael J. Fox Foundation for Parkinson's Research

Photo and Illustration Credits

On the cover

Dopamine neurons and their death in Parkinson's disease. At left and center, cell death in the substantia nigra, the brain region affected in PD. At right, a dopamine neuron expressing LRRK2. LRRK2 mutations are now believed to be the most common genetic contribution to PD. Images courtesy of Robert Burke, PhD, Columbia University (left and center) and Mark Cookson, PhD, National Institute of Aging, National Institutes of Health (right).

Page 3

Photo of Katie Hood: Getty Images/Michael Buckner. Photos of Michael J. Fox and Debi Brooks: WireImage/Kevin Perry.

Page 4

Pre-clinical model cerebellum copyright 2002–2007, The Regents of the University of California. All Rights Reserved. Permission to use, copy, modify, and distribute any part of the Cell Centered Database (CCDB) website for educational, research, and non-profit purposes, without fee, and without a written agreement is hereby granted, provided that the above copyright notice, this paragraph, and the following three paragraphs appear in all copies.

Those desiring to incorporate this CCDB website into commercial products or use for commercial purposes should contact Dr. Maryann Martone at 858-822-0745 and Technology Transfer and Intellectual Property Services, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0910, Phone: (857) 534-5815, Fax: (858) 534-7345, email: invent@ucsd.edu.

In no event shall the University of California be liable to any party for direct, indirect, special, incidental, or consequential damages, including

lost profits, arising out of the use of this CCDB website, even if the University of California has been advised of the possibility of such damage.

The CCDB website provided herein is on an "as is" basis, and the University of California has no obligation to provide maintenance, support, updates, enhancements, or modifications. The University of California makes no representations and extends no warranties of any kind, either implied or express, including, but not limited to, the implied warranties of merchantability or fitness for a particular purpose, or that the use of the CCDB website will not infringe any patent, trademark, or other rights.

Page 5

LRRK2 images courtesy of Mark Cookson.

Page 6

Dopamine neuron images courtesy of John Sinclair.

Pages 8–9

Dopamine schematic courtesy of Dr. Paul Greengard, The Rockefeller University, with the technical assistance of Elisabeth Griggs.

Photo courtesy of Vanderbilt Medical Center.

Crystal structure of G-CSF as published in the Protein Data Bank (PDB: 1RHG), public domain. Created from PDB 1RHG and rendered by Ramin Herati using Pymol, March 10, 2007.

Pages 10–11

Photo of Marina Emborg courtesy of the University of Wisconsin, Madison.

Photo of Wolfgang Oertel courtesy of Philipps University Marburg, Germany.

Photo of nicotine patch: Getty Images.

Pages 12–13

Photo of Angela Cenci-Nilsson courtesy of Lund University, Sweden.

Table depicts data produced in the laboratory of M.A. Cenci at Lund University, Sweden.

Structure of serotonin copyright 2005–2007 Karl Harrison.

Page 14

Photo of Simon Lewis courtesy of the University of Sydney, Australia.

Pages 16–17

Zinc Finger Nuclease schematic courtesy of Sigma-Aldrich.

Photo courtesy of Weill Cornell Medical College.

Pages 20–21

Photos 1, 2, 5, 8, 14: WireImage/Kevin Mazur. Photos 3, 9, 12, 17: Ann Billingsley. Photo 4 courtesy of Amar Kuchinad. Photo 6 courtesy of Drew and Kyle Shackleton. Photos 7, 11, 13: Getty Images/Michael Buckner. Photo 10: Tommy Sandler. Photo 16: Elena Olivo.

Page 40

Elena Olivo.

Page 43

Elena Olivo.

Inside back cover

Yeast cells expressing human alpha-synuclein tagged with a green-fluorescent protein courtesy of Susan Lindquist, Whitehead Institute for Biomedical Research/Aaron Gitler, University of Pennsylvania.

The Michael J. Fox Foundation gratefully acknowledges Bulkley Dunton for donating the high-quality McCoy Silk Cover and Text paper on which this annual report was printed, and Yes Press for printing this report below cost.

Our gratitude to Hearst Corporation for facilitating both donations.

Board of Directors

George E. Prescott

Chairman

David Golub

Vice Chairman

Holly S. Andersen, MD

Eva Andersson-Dubin, MD

Jon Brooks

Barry J. Cohen

Donny Deutsch

David Einhorn

Karen Finerman

Nelle Fortenberry

Michael J. Fox

Albert B. Glickman

Mark L. Hart III

Skip Irving

Kathleen Kennedy

Morton M. Kondracke

Edwin A. Levy

Marc S. Lipschultz

Kenneth Olden, PhD, ScD

Douglas I. Ostrover

Tracy Pollan

Ryan Reynolds

Frederick E. Rowe

Lily Safra

Curtis Schenker

Woody Shackleton

Fred G. Weiss

Founders' Council

Lonnie and Muhammad Ali

Steven A. Cohen

John A. Griffin

Andrew S. Grove

Jeffrey Katzenberg

Nora McAniff

Donna E. Shalala, PhD

Leadership Council

Scott Scheffrin

Chairman

Claire Capello

Dev Chodry

Sonya Chodry

Anne-Cecilie Engell Speyer

Richard Fitzgerald

Lee Fixel

Sean Goodrich

Amar Kuchinad

Joella Lykouratzos

Patient Council

Eugenia Brin

Carey Christensen

David Eger, PhD

David Iverson

Soania Mathur, BSc, MD, CCFP

Thomas A. Picone, PhD

Richard Rothenberg

W.N. "Bill" Wilkins

Scientific Advisory Board

Gene Johnson, PhD

*Chief Scientific Advisor**

Irene Hegeman Richard, MD

*Senior Medical Advisor**

Alberto Ascherio, MD, DrPH

Erwan Bezard, PhD

Anders Björklund, MD, PhD

Susan Bressman, MD*

Robert E. Burke, MD

Angela Cenci-Nilsson, MD, PhD

Marie-Françoise Chesselet, MD, PhD

P. Jeffrey Conn, PhD

Mark Cookson, PhD*

David Eidelberg, MD

Matthew Farrer, PhD

Charles (Chip) Gerfen, PhD

J. Timothy Greenamyre, MD, PhD

Franz F. Hefti, PhD

Etienne C. Hirsch, PhD

Oleh Hornykiewicz, MD

Ole Isacson, MD (Dr Med Sci)

Joseph Jankovic, MD*

Jennifer Johnston, PhD

Jeffrey H. Kordower, PhD

J. William Langston, MD

Frans Olof (Olle) Lindvall, MD, PhD

Andres Lozano, MD, PhD

Kenneth Marek, MD

Eldad Melamed, MD

Kalpana Merchant, PhD

C. Warren Olanow, MD

Bernard M. Ravina, MD, MSCE

Peter H. Reinhart, PhD

Ira Shoulson, MD

Andrew Singleton, PhD *

David G. Standaert, MD, PhD


Dennis A. Steindler, PhD

Caroline Tanner, MD, PhD

David Weiner, MD*

Michael Zigmond, PhD

* Executive Committee





Church Street Station
P.O. Box 780
New York, NY 10008-0780
(800) 708-7644
www.michaeljfox.org